Epigenetic Reprogramming In Tumor Plasticity by Yuan, Salina
University of Pennsylvania 
ScholarlyCommons 
Publicly Accessible Penn Dissertations 
2020 
Epigenetic Reprogramming In Tumor Plasticity 
Salina Yuan 
University of Pennsylvania 
Follow this and additional works at: https://repository.upenn.edu/edissertations 
 Part of the Cell Biology Commons, and the Molecular Biology Commons 
Recommended Citation 
Yuan, Salina, "Epigenetic Reprogramming In Tumor Plasticity" (2020). Publicly Accessible Penn 
Dissertations. 3983. 
https://repository.upenn.edu/edissertations/3983 
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3983 
For more information, please contact repository@pobox.upenn.edu. 
Epigenetic Reprogramming In Tumor Plasticity 
Abstract 
During cancer progression, tumor cells undergo various molecular and phenotypic changes collectively 
referred to as “plasticity,” leading to both cell autonomous and non-cell autonomous consequences. There 
is increasing evidence that epigenetic modifiers – enzymes and complexes involved in the removal, 
deposition, and molecular interpretation of chromatin post-translational modifications – play an 
important role in regulating tumor plasticity. Still, our understanding of how or even the extent to which 
chromatin-based mechanisms contribute to tumor biology remains limited. Here we employed CRISPR-
based forward genetic screening to unbiasedly address the epigenetic basis of tumor plasticity. Through 
an in vitro screen, we first identified two histone-modifying enzymes involved in the writing and erasing of 
H3K36me2 that act reciprocally to regulate epithelial plasticity, a particular form of cellular plasticity 
whereby cells transition between epithelial and mesenchymal states, as well as tumor differentiation and 
metastasis. Mechanistically, we found that global changes in H3K36me2 reprogram enhancers 
associated with master transcriptional regulators of the mesenchymal state. While these results indicate 
that a large-scale, epigenome-wide mechanism underlies epithelial plasticity in cancer, we subsequently 
identified focal epigenetic alterations as the basis for microenvironmental plasticity. Specifically, using an 
in vivo CRISPR-Cas9 screen, we identified the histone demethylase KDM3A as a potent tumor cell-intrinsic 
epigenetic regulator of the immune microenvironment. Through transcriptomic and epigenomic analyses, 
we found that KDM3A and its two downstream mediators, KLF5 and SMAD4, transcriptionally converge 
on EGFR to suppress T cell infiltration, and that loss of any of the components of this molecular axis is 
sufficient to convert the immune microenvironment from non-T cell-inflamed to T cell-inflamed, thereby 
sensitizing tumors to combination immunotherapy. Thus, using the power of CRISPR genetic screening, 
we identified key epigenetic determinants of cellular plasticity, which lead to both cell intrinsic and 
extrinsic changes. These epigenetic modifiers also represent a promising class of therapeutic targets for 
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During cancer progression, tumor cells undergo various molecular and phenotypic 
changes collectively referred to as “plasticity,” leading to both cell autonomous and non-cell 
autonomous consequences. There is increasing evidence that epigenetic modifiers – enzymes and 
complexes involved in the removal, deposition, and molecular interpretation of chromatin post-
translational modifications – play an important role in regulating tumor plasticity. Still, our 
understanding of how or even the extent to which chromatin-based mechanisms contribute to tumor 
biology remains limited. Here we employed CRISPR-based forward genetic screening to 
unbiasedly address the epigenetic basis of tumor plasticity. Through an in vitro screen, we first 
identified two histone-modifying enzymes involved in the writing and erasing of H3K36me2 that act 
reciprocally to regulate epithelial plasticity, a particular form of cellular plasticity whereby cells 
transition between epithelial and mesenchymal states, as well as tumor differentiation and 
metastasis. Mechanistically, we found that global changes in H3K36me2 reprogram enhancers 
associated with master transcriptional regulators of the mesenchymal state. While these results 
indicate that a large-scale, epigenome-wide mechanism underlies epithelial plasticity in cancer, we 
subsequently identified focal epigenetic alterations as the basis for microenvironmental plasticity. 
Specifically, using an in vivo CRISPR-Cas9 screen, we identified the histone demethylase KDM3A 
as a potent tumor cell-intrinsic epigenetic regulator of the immune microenvironment. Through 
transcriptomic and epigenomic analyses, we found that KDM3A and its two downstream mediators, 
KLF5 and SMAD4, transcriptionally converge on EGFR to suppress T cell infiltration, and that loss 
of any of the components of this molecular axis is sufficient to convert the immune 
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microenvironment from non-T cell-inflamed to T cell-inflamed, thereby sensitizing tumors to 
combination immunotherapy. Thus, using the power of CRISPR genetic screening, we identified 
key epigenetic determinants of cellular plasticity, which lead to both cell intrinsic and extrinsic 
changes. These epigenetic modifiers also represent a promising class of therapeutic targets for 
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CHAPTER 1: Introduction  
 
 
Cellular plasticity and tumor progression 
 
The ability of cells to adopt different identities along a phenotypic spectrum is a 
phenomenon broadly known as cellular plasticity. Although it is a signature feature of embryonic 
differentiation, cellular plasticity has also been widely observed in terminally differentiated adult cell 
populations in various contexts. Most notably, cells may transition through different phenotypes 
when faced with chronic physiologic and pathologic stresses. Under such circumstances, cellular 
plasticity serves as a mechanism of tissue adaptation or regeneration, but it can also predispose 
tissues to cancerous transformation.  
While loss of normal cell identity and function is inherent to the malignant process, cancer 
cells undergo further phenotypic changes during tumor progression and treatment. Tumor cells are 
exposed to diverse metabolic conditions, signaling molecules, stromal elements, and therapeutic 
agents, which collectively form a volatile microenvironment that can fuel changes in cellular 
phenotype and identity. Such changes may involve genetic alterations, but they more commonly 
occur because of transcriptional or epigenetic fluctuations. The resulting pliability in cell state leads 
to both cell autonomous and non-cell autonomous consequences, and can thus facilitate multiple 
aspects of tumor progression, including initiation, changes to the tumor microenvironment including 
immune evasion, metastasis, and chemoresistance. As a result, elucidating the mechanisms by 
which cancer cells use plasticity to cope with selective pressures may lead to novel therapeutic 
opportunities. 
One of the most well-known examples of cellular plasticity is the epithelial-to-mesenchymal 
transition (EMT), the process by which cells of epithelial origin dissolve their cell-cell junctions, lose 
their apical-basal polarity, and in turn acquire the morphologic and invasive phenotypes reminiscent 
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of fibroblasts (Figure 1). Molecularly, EMT involves a transcriptional reprogramming that includes 
the repression of genes whose protein products are necessary for maintenance of the epithelial 
state (e.g. junctional complexes and epithelial intermediate filaments) and the concomitant 
induction of genes associated with the mesenchymal state, including the mesenchymal 
intermediate filament protein Vimentin (Vim) and components of the extracellular matrix (ECM). 
EMT is essential for normal development and its absence leads to problems with gastrulation, 
neural crest migration, and other severe developmental abnormalities (1). While critical for normal 
embryonic development, EMT is also frequently observed in many carcinomas (i.e. tumors of 
epithelial origin) and has been associated with various clinical factors that portend poor prognosis. 
In carcinomas, the degree to which cancer cells have undergone an EMT program is reflected in a 
tumor’s grade. High-grade disease is aggressive and marked by an obliteration of normal tissue 
structure and architecture. Such tumors – often referred to as “poorly differentiated” – bear the 
histopathological and molecular hallmarks of EMT. By contrast, low-grade disease is characterized 
by a “moderately-to-well differentiated” histology that reflects the cancer cells’ retention of an 
epithelial phenotype. Across human cancer, high-grade (poorly differentiated) tumors carry a worse 
prognosis. Importantly, such grading schemes describe the dominant cellular phenotype within a 
tumor and thus fail to capture the dynamic plasticity that exists in cancer. Rather than being wholly 
comprised of cancer cells with either a mesenchymal or an epithelial phenotype, most tumors are 
composites of the two phenotypes existing in equilibrium. In poorly-differentiated tumors, this 
equilibrium is shifted to the mesenchymal state, while in well-differentiated tumors it is shifted to 
the epithelial state. Thus, it is the relative abundance of cells in either state that indicates the grade 
of a tumor.   
EMT is often associated with increased metastatic disease. When EMT is induced in tumor 
cells, either pharmacologically by treatment with certain signaling factors (e.g. TGFβ, EGF, HGF, 
NOTCH, FGF, and WNT ligands) or genetically by overexpression of known master EMT 
transcription factors (EMT-TFs)  (e.g. SNAIL, TWIST, ZEB, and PRRX family members), they 
acquire the characteristic spindle-like morphology and readily delaminate from their neighbors. This 
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has been widely observed in vitro, and, with more advanced live imaging techniques, it has also 
been recently captured in vivo. However, in the clinical setting, metastatic lesions commonly exhibit 
an epithelial appearance in histopathology, posing a problem for models emphasizing the 
importance of EMT in metastasis. This apparent paradox has been explained by the reversibility of 
the mesenchymal phenotype by a mesenchymal-to-epithelial transition (MET), which has been 
shown to be important for the last steps of the metastatic cascade, namely colonization of a distant 
site (2–5). Therefore, while the more motile phenotypes associated with EMT may facilitate spread 
and dissemination from the primary tumor, the greater cellular cohesiveness associated with MET 
may foster successful metastatic outgrowth. This level of plasticity complicates efforts to target 
EMT as a strategy to inhibit metastasis, and ongoing work seeks to address this point.  
  Epithelial-mesenchymal plasticity also appears to influence sensitivity to therapeutic 
agents. In general, resistance to therapy is more commonly associated with a mesenchymal state 
than an epithelial state. For example, the expression of an EMT-related gene signature in tumors 
has been associated with resistance to neoadjuvant therapy in breast cancer and to inhibitors of 
the epidermal growth factor receptor (EGFR) and PI3 kinase (PI3K) in non-small cell lung cancer 
(NSCLC) (6–9). These clinical studies are in line with cell culture experiments, suggesting that well-
differentiated tumor cell lines (exhibiting an epithelial phenotype) are more sensitive to EGFR 
inhibitors than poorly differentiated tumors (exhibiting a mesenchymal phenotype). More recently, 
EMT has also been associated with resistance to immunotherapy (10). In murine melanoma cells, 
for example, the master EMT-TF SNAIL is necessary and sufficient for resistance to dendritic cell 
and cytotoxic T cell-mediated killing (11). Likewise, melanomas that are innately resistant to 
immune checkpoint blockade (ICB) display a transcriptional signature reminiscent of EMT-related 
processes, including the downregulation of the epithelial junction protein E-cadherin (Ecad) and 
the concomitant upregulation of mesenchymal factors involved in extracellular matrix remodeling, 
angiogenesis, and wound healing (12).  
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Cancer cells exist within a complex tumor microenvironment (TME) comprised of 
fibroblasts, endothelial cells, leukocytes, and extracellular matrix. While these TME components 
are known to exert a powerful influence on the phenotype and function of cancer cells, reciprocal 
signaling from cancer cells can also have potent effects on the TME. Thus, a change in the 
phenotype of a cancer cell (as a result of cellular plasticity) can have a marked influence on 
surrounding non-cancer cells. Of particular interest is the idea that tumor cells can act as architects 
of the immune TME. Indeed, SNAIL-induced EMT in breast cancer cells promotes a pro-tumor 
inflammatory microenvironment by upregulating the production of cytokines including CSF2, IL1α, 
IL-6, and TNFα (13). Likewise, ZEB1-mediated EMT in NSCLC cells results in increased tumor 
programmed cell death 1 ligand 1 (PD-L1) expression, thus reducing the total number and activity 
of tumor-infiltrating CD8+ lymphocytes (14). Outside of EMT-related plasticity, recent work has 
shown that tumor cell expression of several key cytokines and chemokines, such as PTGS2 (15), 
and CSF2 (16,17), is sufficient to attract immunosuppressive myeloid-derived suppressor cells 
(MDSCs) and exclude effector CD8 T cells from the tumor. Inhibiting any of these factors can 
promote a “T cell high” environment and sensitizes the tumor to immunotherapy (Figure 2). To what 
extent these “T cell high” and “T cell low” phenotypes represent distinct cell states and whether 
these states are plastic remains uncertain. Several transcription factors and epigenetic modifiers, 
such as KDM1A (18) and USP22 (19,20), have been implicated as master regulators of the immune 
TME, suggesting that tumor cell intrinsic determination of the immune TME may indeed be a feature 
of specific cell identity states.  
Tumor cells display a remarkable ability to change, leading to alterations at both the cellular 
and microenvironmental level. These changes enable the developing tumor to adapt to constantly 
changing conditions and withstand various therapeutic pressures. Thus, tumor plasticity represents 
an important hallmark of cancer, and though the mechanisms that underlie this process are no 
doubt diverse and complex, a better understanding of how this phenomenon occurs will be critical 
for future therapeutic interventions.  
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Epigenetic regulation of cell identity in cancer 
Chromatin, a complex of DNA and histone proteins, serves as the physiologically relevant 
form of the eukaryotic genome, and is the essential medium through which transcription factors 
(TFs), signaling pathways, and other cues alter gene activity and cellular phenotypes. Dynamically 
regulated by epigenetic modifiers – i.e. enzymes and complexes involved in the restructuring of 
chromatin components or the removal, deposition, and molecular interpretation of chromatin 
covalent chemical modifications – chromatin state is important for the establishment and 
maintenance of cell identity. As such, aberrations in chromatin are associated with a wide range of 
diseases, including cancer. Although cancer is typically considered a genetic disease, epigenetic 
dysregulation has been increasingly implicated in many aspects of the disease. In fact, an 
unanticipated outcome of large-scale cancer genome sequencing projects is the finding that 
roughly 50% of human cancers harbor mutations in chromatin-associated proteins (21–23). 
Malignant cells also exhibit genome-wide alterations in DNA methylation, chromatin structures, and 
regulatory element activities. In addition, many tumors exhibit dedifferentiated developmental 
programs and loss of normal cell/lineage identity, indicative of aberrant epigenetic reprogramming 
(21,24). 
 The human genome comprises thousands of gene-coding loci as well as non-coding 
proximal and distal regulatory elements (promoters and enhancers, respectively) that control gene 
activity in specific cell types. The activity of a locus is closely tied to its chromatin organization. 
Active genes and elements must be accessible to regulatory factors and transcriptional machinery, 
whereas inactive loci are sequestered within compact and inaccessible structures that prevent their 
inappropriate activity (25,26). For example, under normal homeostatic conditions, context-specific 
repression of lineage-specific developmental genes is enforced by Polycomb repressor complexes 
(PRCs), such as the histone H3 lysing residue 27 (H3K27) methyltransferase EZH2 (enhancer of 
zeste homolog 2) (26,27). Repetitive sequences and gene deserts are silenced by heterochromatin 
structures, DNA methylation, H3K9 methylation, and lamin-associated factors. Conversely, active 
loci may be sustained by TFs and chromatin modifying cofactors that bind promoters and 
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enhancers, engage RNA polymerase, and stimulate transcriptional activity. These regulatory 
activities present a potent barrier to chromatin repression and compaction, thereby facilitating the 
maintenance of the active state (28,29). Because any single locus can assume different 
transcriptional states in different cellular contexts, the chromatin state must be capable of 
responding to appropriate cues and conditions. The likelihood that a locus will respond to a signal 
is dependent on the expression of TFs and their recruitment to the locus, as well as the activity of 
epigenetic modifiers responsible for both the local chromatin state and the global chromatin 
environment in the cell.  
Alterations to the DNA methylation landscape are frequently observed in various tumors. 
In normal cells, cytosines in CpG islands and other CG-rich loci are largely unmethylated, whereas 
cytosines in CG-poor regions tend to be highly methylated. In many cancers, this pattern is flipped 
as CpG islands become hypermethylated and CG-poor regions become hypomethylated. The 
former aberration has been termed CpG island methylator phenotype (CIMP) and has been 
described in a wide range of phenotypically diverse tumors. CpG island hypermethylation can 
silence and/or prevent reactivation of the tumor suppressor p16 and DNA mismatch repair genes, 
such as MLH1 and MSH2 (30,31). On the other hand, in some leukemias, DNA methyltransferase 
(DNMT) mutations can lead to hypomethylation, resulting in aberrant gene activation and 
oncogenesis (32,33). Furthermore, as tumor cells undergo rapid rounds of replication, the DNA 
methylation landscape exhibits increased heterogeneity and variability genome-wide (34). This 
instability has been linked to stochastic activation of cancer-associated genes, including cell cycle– 
and EMT–related genes (35). 
Recurrent mutations in the genes encoding histone modifiers are also likely to disrupt 
normal transcriptional regulation, potentially leading to malignant transformation due to loss of 
normal cell identity. For example, gain and loss of histone lysine demethylase (KDM) activity have 
been widely implicated in cancer. H3K4 demethylases enable lung and melanoma cell lines to 
evade antiproliferative therapies by adopting a slow-cycling state (36,37). H3K27 demethylases 
enable glioblastoma stem cells to tolerate similar drug pressures by regressing to a more “primitive” 
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developmental state (38) and pancreatic ductal adenocarcinoma (PDA) cells to adopt a more 
aggressive, poorly differentiated phenotype (39). And KDM4 family enzymes, which demethylate 
H3K9 and H3K36, are up-regulated in many cancer types, where they deregulate heterochromatin, 
affect replication timing, and prime chromosomal copy number alterations (40).  
Among the most widely studied epigenetic perturbations in cancer include those that affect 
the activity of PRCs, whose primary function is to tri-methylate H3K27 across the genome. For 
example, gain-of-function EZH2 mutations, which leads to PRC2 hyperactivity, are frequent in 
several lymphoma subtypes and have also been detected in melanoma (41). Genome-wide 
analyses of EZH2 mutant lymphomas revealed expansive H3K27 trimethylation (H3K27me3) and 
depletion of active chromatin marks over loci encoding terminal differentiation genes. The 
tumorigenic mutants thus appear to induce a restrictive state that prevents induction of 
differentiation genes and arrests B cells in a more proliferative, developmentally immature state 
(42). EZH2 activity is opposed by a number of mechanisms, including demethylases that remove 
H3K27 methylation (e.g. KDM6A/B), modifying enzymes that catalyze H3K27 acetylation, H3K36 
methylation, or H3K4 methylation (e.g. p300, NSD2, and MLL components, respectively), and by 
nucleosome remodelers (e.g. ARID1A/B and other SWI/SNF members) (25,43). A number of these 
enzymes are also genetically inactivated in a wide range of cancers (30,44), and appear to 
functionally cooperate with or mimic EZH2 gain-of-function mutations. For example, inactivating 
MLL2 and CBP/p300 mutations in lymphoma impede appropriate engagement of promoters or 
enhancers needed for differentiation (45). And in pediatric malignant rhabdoid tumors, homozygous 
inactivation of the nucleosome remodeling enzyme SNF5 disables enhancers associated with 
mesenchymal differentiation genes, many of which are PRC2 targets (46).  
To further complicate matters, epigenetic modifiers and their mutant activities often exhibit 
tissue- and context-specific effects. For example, though EZH2 gain-of-function mutations may be 
oncogenic in B cell lineages, EZH2 loss-of-function mutations are tumorigenic in other settings, 
such as myelodysplastic syndromes (MDS), T cell acute lymphoblastic leukemia (T-ALL), and other 
cancers (41). In multiple myeloma, activating mutations in NSD2, the enzyme that catalyzes H3K36 
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di-methylation (H3K36me2), limits EZH2-mediated H3K27me3 spreading to induce tumorigenesis 
(47). In pediatric brain tumors, somatic mutations of the histone substrate itself, specifically the 
H3.3 Lys27 → Met (H3K27M) oncohistone, dominantly suppresses EZH2 function (48–51).  And 
in pediatric chondroblastomas, the H3K36M oncohistone dominantly suppresses NSD2 and 
SETD2 function, leading to intergenic loss of H3K36 di and trimethylation (H3K36me2/3) and a 
concomitant spreading of H3K27me3 (52,53). In this model, EZH2 activity is actually diluted away 
from repressed genic loci, leading to ectopic gene expression contributing to the dedifferentiation 
of chondrocytes. Thus, suppression of PRC activity by EZH2 inactivation or histone mutation may 
create an overly permissive chromatin state that allows spurious gene activation and prevents 
differentiation-associated silencing. 
Many epigenetic modifiers are amenable to pharmacologic targeting and a new class of 
epigenetic-based therapies are actively being tested in clinical trials. In acute myelocytic leukemia 
(AML), inhibition of lysine-specific demethylase 1 (LSD1; also known as KDM1A) leads to 
epigenetic reactivation of the retinoic acid differentiation program and tumor regression (54). Pan-
histone deacetylase (HDAC) inhibitors, such as sodium butyrate, and inhibitors of bromodomain-
containing protein 4 (BRD4) have also emerged as promising differentiation therapies for AMLs 
(55–57) by disrupting major oncogenic transcriptional networks. In a subset of low-grade gliomas, 
mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) lead to the formation of an 
oncometabolite (2-hydroxyglutarate; 2HG), which drives extensive CpG hypermethylation and 
induces the expression of a proneural gene signature and a stem-like phenotype. Treatment of 
patient-derived IDH1 mutant glioma cells with the DNMT inhibitor decitabine reversed the 
widespread DNA methylation, induced the re-expression of genes associated with differentiation, 
and slowed tumor progression (58). More recently, a small molecule screen identified bromodomain 
inhibitors such as JQ1 and iBET as being synthetically lethal with the genetic loss of KDM6A in 
PDA (39). Together, these studies showcase the therapeutic promise of epigenetic-based 




Current therapeutic landscape for PDA 
Pancreatic ductal adenocarcinoma (PDA) is projected to become the second leading cause 
of cancer-related deaths in the United States by 2030 (59). The overall 5-year survival rate has 
changed little over the past few decades, and currently stands at less than 9% (60). Surgery 
remains the only chance for cure, but the vast majority of cases present as metastatic disease at 
the time of diagnosis and are thus ineligible for surgical resection. Still, surgery alone is often not 
enough, as >90% of patients relapse and die of their disease after potentially curative surgery 
without additional therapy (61,62). Adjuvant and neoadjuvant treatment strategies have therefore 
been evaluated during the past several decades, demonstrating slow but steady improvements.  
In terms of adjuvant and neoadjuvant chemotherapies, the standard of care for the last 
fifteen years has been gemcitabine, a nucleoside analog that causes apoptosis by inhibiting DNA 
replication. More recently, clinical trials have attempted to combine gemcitabine with other drugs, 
but few have yielded improvements. One successful combination, gemcitabine plus the microtubule 
inhibitor nab-paclitaxel, increased median overall survival by 1.8 months and is considered the new 
standard of care in America. Another more aggressive four-drug regimen consisting of fluorouracil, 
irinotecan, oxaliplatin, and leucovorin (FOLFIRINOX) also increases median overall survival 
compared to gemcitabine alone (11.1 months vs. 6.8 months, respectively), but is used less 
frequently because of its side effects (63). In the majority of cases where surgery is not an option, 
aggressive treatment with these chemotherapies, occasionally in combination with radiation, is 
attempted to temporarily control the disease.  
To identify more effective treatment combinations, numerous targeted agents have been 
evaluated alongisde chemotherapy, though most have so far failed to improve patient survival. The 
long list of targeted compounds tested in trials includes antiangiogenic drugs, such as vascular 
endothelial growth factor (VEGF) inhibitors (64), and compounds targeting signaling cascades 
known to be important for PDA oncogenesis, such as anti-insulin-like growth factor 1 receptor 
antibodies and phosphoinositide 3-kinase (PI3K) inhibitors (65–67). The only targeted agent to 
have exhibited a statistically significant, but clinically marginal, effect on patient survival is the 
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EGFR inhibitor erlotinib, conferring a mean survival benefit of ~2 weeks in combination with 
gemcitabine over gemcitabine alone (68). Since activating KRAS mutations occur in up to 90% of 
patients with PDA, it is thought that pharmacological inhibition of EGFR upstream of KRAS is only 
minimally effective in this cancer type, thus leading to modest clinical benefit.  
Immunotherapy has emerged as a promising treatment modality in many tumor types. In 
particular, inhibition of proteins involved in T cell checkpoints, such as cytotoxic T lymphocyte 
protein 4 (CTLA4) and programmed cell death protein 1 (PD-1) shows enormous promise in a 
number of cancer types, most notably, melanoma. However, to date, PDA has proved refractory to 
these agents, likely reflecting the immunosuppressive nature of the PDA microenvironment. 
Mechanisms by which cancer inhibits the immune response broadly include suppression of both 
effector CD8 T cell activity and intratumoral infiltration. Clinically, one of the most robust indicators 
of potent immune checkpoint blockade (ICB) response is the number of T cells in the primary tumor 
(69). As such, current efforts include devising ways to increase intratumoral T cell abundance. 
Although pancreatic cancer is predicted to become the second leading cause of cancer-
associated mortality within the next decade, there has recently been steady progress in improving 
outcomes. Still, the challenges that remain are substantial, and further insight into PDA’s complex 
biology will be paramount. One of the reasons why PDA remains so refractory to almost all 
treatment modalities may be the high degree of molecular heterogeneity that characterizes both 
the tumor cells themselves, as well as the surrounding stromal elements. One of the key 
mechanisms underlying tumor heterogeneity is cellular plasticity and the wide phenotypic spectrum 
that results. Thus, attempts at designing a more generalized, “one size fits all” treatment strategy 
will be immensely challenging and will likely hinge on a far better understanding of the mechanisms 








Figure 1: Epithelial plasticity in cancer. The epithelial-to-mesenchymal transition (EMT) is a 
cellular process that leads to loss of epithelial identity and concomitant gain of the mesenchymal 
fate. This is transcriptionally driven by master EMT transcription factors, such as SNAI1/2, 
TWIST1/2, and ZEB1/2, which downregulate the expression of cell-to-cell junctions and upregulate 
the expression of pro-migratory factors. During tumor progression, EMT is associated with 
increased invasiveness and therapy resistance, while the mesenchymal-to-epithelial transition 







Figure 2: Tumor immune microenvironment plasticity. The “immune cold” microenvironment is 
characterized by a greater abundance of immunosuppressive immune cells, such as myeloid-
derived suppressor cells (MDSCs), and fewer CD8 T cells and dendritic cells. Recent studies have 
shown that tumor cells are master organizers of this microenvironment by secreting cytokines and 
chemokines like CSF2 and PTGS2. Tumors characterized by an abundance of CD8 T cells (i.e. 
“immune hot”) are more sensitive to immunotherapy.  
“Immune hot” “Immune cold” 
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CHAPTER 2: Global regulation of the histone mark H3K36me2 underlies epithelial 




Epithelial plasticity – reversible modulation of a cell’s epithelial and mesenchymal features 
– is associated with tumor metastasis and chemoresistance, leading causes of cancer mortality. 
While different master transcription factors and epigenetic modifiers have been implicated in this 
process in various contexts, the extent to which a unifying, generalized mechanism of 
transcriptional regulation underlies epithelial plasticity remains largely unknown. Here, through 
targeted CRISPR-Cas9 screening, we discovered two histone-modifying enzymes involved in the 
writing and erasing of H3K36me2 that act reciprocally to regulate epithelial-mesenchymal identity, 
tumor differentiation, and metastasis. Using a K-to-M histone mutant to directly inhibit H3K36me2, 
we found that global modulation of the mark is a conserved mechanism underlying the 
mesenchymal state in various contexts. Mechanistically, regulation of H3K36me2 reprograms 
enhancers associated with master regulators of epithelial-mesenchymal state. Our results thus 
outline a unifying epigenome-scale mechanism by which a specific histone modification regulates 













Cancer cells are capable of dramatic changes in phenotype and function, a phenomenon 
known as cellular plasticity (70). Epithelial-to-mesenchymal transition (EMT, i.e. epithelial 
plasticity), and its reverse process (MET), are among the most widely studied examples of cellular 
plasticity; these programs are utilized during embryonic development for tissue morphogenesis and 
are frequently reactivated during tumor progression (1). In particular, histological and transcriptomic 
signatures relevant to EMT are frequently associated with metastasis, therapeutic resistance, and 
other factors portending poor prognosis and patient mortality (71).    
The cellular hallmarks of EMT, which include repression of epithelial proteins such as E-
cadherin, Occludin, and Zo-1, and induction of mesenchymal proteins such as N-cadherin, 
Vimentin, and Fibronectin, are classically induced by a small cohort of master EMT-related 
transcription factors (“EMT-TFs”) including Snai1/2, Twist1/2, and Zeb1/2 (1). However, the relative 
importance of each of these transcription factors varies depending on experimental and clinical 
contexts, leading to seemingly conflicting reports on the roles they play in EMT and cancer 
progression (72–74). Such findings raise the possibility that a more generalized mechanism or 
common molecular feature might exist that could unify the activity of these EMT-TFs. 
Epigenetic modifiers and complexes can enact broad, genome-wide changes in 
transcription; such global epigenetic alterations have been reported to underlie other cell fate 
changes, particularly during normal embryonic development (75,76). In tumor cells, several EMT-
TFs have previously been reported to functionally cooperate with various epigenetic modifiers (77); 
however, such studies have focused on interactions at the promoters of pre-selected epithelial and 
mesenchymal genes (78–84). And while previous profiling efforts have identified genome-scale 
changes in DNA methylation (85) and certain histone marks (86) during experimentally-induced 
EMT, it remains uncertain whether these epigenetic changes are necessary and/or sufficient to 
induce cancer cell plasticity or whether they represent correlated (secondary) events. In the current 
study, we took an unbiased genetic approach to identify epigenome-wide mechanisms driving 
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epithelial plasticity and metastatic progression, and directly interrogated the functional role of 





























Modeling epithelial plasticity in vitro 
To better understand epigenetic mechanisms underlying epithelial plasticity, we 
established an experimental system relying on stochastic changes in cell state rather than genetic 
or chemical induction. We began by utilizing a panel of single cell clones derived from the KPCY 
(LSL-KrasG12D; P53loxP/+; Pdx1-cre; LSL-RosaYFP/YFP) mouse model of pancreatic ductal 
adenocarcinoma (PDAC) (87). Clones retained both epithelial and mesenchymal subpopulations, 
as defined by the presence or absence of surface E-cadherin (Ecad) (88) and other classical 
epithelial or mesenchymal markers (Figures 1A-B and Supplementary Figure S1A). To confirm that 
epithelial plasticity is associated with global differences in chromatin landscape, we performed 
ATAC-seq on FACS-sorted Ecad+ versus Ecad- cells and identified chromatin regions exhibiting 
differential accessibility. Ecad- cells exhibited greater accessibility in genes associated with a 
mesenchymal phenotype and/or epithelial-mesenchymal transition (EMT) (Figure 1C and 
Supplementary Figure S1B). By contrast, Ecad+ cells exhibited greater accessibility in genes 
associated with an epithelial phenotype, including Ecad itself (Figure 1C). Thus, FACS sorting 
based on surface Ecad expression isolates cell populations with distinct chromatin profiles, 
reflecting transcriptional programs related to epithelial-mesenchymal state. 
Next, we sought to ensure that the Ecad+ and Ecad- fractions do not represent fixed, non-
plastic subpopulations. To this end, we sorted pure populations of Ecad+ or Ecad- cells. Over a 2-
4-week period after initial sorting, all cultures exhibited phenotypic reversion (i.e. Ecad+ cells 
became Ecad-, and Ecad- cells became Ecad+) (Figure 1D). Remarkably, all cultures returned to 
an equilibrium that recapitulated the Ecad+/Ecad- ratio observed in the parental culture (Figure 1D, 
dotted line). Thus, these cell clones exhibit dynamic plasticity (i.e. both epithelial and mesenchymal 
transitions) under standard culture conditions. 
 
CRISPR-Cas9 screen identifies epigenetic regulators important for EMT   
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To identify epigenetic modifiers important for plasticity, we carried out a focused CRISPR-
Cas9 screen using an sgRNA library targeting ~600 epigenetic modifiers and controls in a clonal 
cell line (3077 c4) stably expressing Cas9 (Figure 1E). As expected, control sgRNAs targeting Zeb1 
– which we had identified as the most potent EMT-TF in this cell line (Supplementary Figure S2A-
D) – were significantly enriched in the Ecad+ population and depleted in the Ecad- fraction. 
Conversely, sgRNAs targeting Ecad exhibited the opposite pattern (Figure 1F). Furthermore, 
sgRNAs targeting ribosomal proteins were depleted in both fractions, while the representation of 
control non-targeting sgRNAs did not change (Supplementary Figures S3A-B).  
Among the sgRNAs showing significant enrichment or depletion in the Ecad+ or Ecad- 
populations, nuclear receptor binding SET domain protein 2 (Nsd2) emerged as the top gene for 
which all targeting sgRNAs were significantly enriched in the Ecad+ subpopulation (Figure 1F and 
Supplementary Figure S3C), second only to Zeb1. Nsd2 is a histone methyltransferase that di-
methylates histone H3 at lysine-36 (H3K36me2), a mark associated with actively transcribed genes 
(89), and acts as an oncogenic driver in multiple myeloma (47) and a regulator of invasion and 
metastasis in prostate cancer (90–92). Conversely, sgRNAs targeting lysine-specific demethylase 
2A (Kdm2a) were significantly overrepresented in the Ecad- subpopulation (Figure 1F and 
Supplementary Figure S3D). Kdm2a is a demethylase that preferentially targets H3K36me2 (93–
95). Both Nsd2 and Kdm2a have paralogs with similar catalytic activities, but none of these were 
enriched or depleted in our screen (Supplementary Figures S3C-F), possibly due to low levels of 
expression (Supplementary Figure S3G). These results suggest that Nsd2 and Kdm2a act non-
redundantly on H3K36 as determinants of the mesenchymal or epithelial state, respectively. 
To validate the role of Nsd2 and Kdm2a in epithelial plasticity, we performed gain- and 
loss-of-function studies in a panel of mouse and human PDAC cell lines. Nsd2 loss led to an 
increase in Ecad levels and decrease in H3K36me2 levels (Figure 1G), while loss of Kdm2a 
resulted in reduced Ecad and increased H3K36me2 (Figure 1H). Both of these phenotypes could 
be rescued by re-expression of the appropriate gene (Figure 1I and J). Importantly, despite lower 
expression of the catalytically active mutant NSD2 (E1099K) (96), this mutant potently reversed 
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the effects of Nsd2 loss, suggesting that Nsd2’s histone methyltransferase activity is critical for 
EMT. Notably, these manipulations had little effect on H3K36me3 levels, in line with previous 
observations (47,97), implying that gain or loss of the H3K36me2 mark is regulated independently 
of effects on higher order methylation. The opposing catalytic activities of Nsd2 and Kdm2a, 
together with their shared substrate specificity, thus implicate a mechanism wherein the writing and 
erasing of H3K36me2 regulates a cell’s position along the epithelial-mesenchymal spectrum.  
 
Nsd2 and Kdm2a reciprocally regulate tumor differentiation and tumor initiation capacity 
To understand the transcriptional changes regulated by Nsd2 and Kdm2a, we carried out 
RNA sequencing (RNA-seq) and gene set enrichment analyses (GSEA) in clonal wild type, sgNsd2, 
and sgKdm2a cells. “EMT” was among the most significantly affected hallmark gene sets (Figure 
2A), and many classic markers of EMT were downregulated with Nsd2 loss and upregulated with 
Kdm2a loss (Supplementary Figure S4A-D). Importantly, many other hallmark and curated gene 
sets enriched following Nsd2 loss were negatively enriched by Kdm2a loss, and vice versa 
(Supplementary Figure S5A-C), suggesting that these enzymes regulate a shared transcriptomic 
program in a reciprocal manner.  
In the clinical setting, the squamous subtype of PDAC describes a subset of tumors that 
are poorly differentiated and of particularly poor prognosis (98–100). Using gene expression 
signatures that discriminate the squamous subtype from the well-to-moderately differentiated 
progenitor subtype in patient samples (101), we found that Nsd2 loss results in negative enrichment 
of the squamous signature and positive enrichment of the progenitor signature, with a converse 
pattern observed in the setting of Kdm2a loss (Figure 2B). These subtype changes are also 
reflected in the differentiation status of cultured cells and tumors arising from these cells (Figure 
2C). These results suggest that Nsd2 and Kdm2a exert opposing effects on cellular transcriptomes, 
leading to changes in tumor subtype and differentiation.  
Since Nsd2 appears to drive a PDAC subtype of particularly poor prognosis, we wished to 
evaluate its prognostic value across various cancer types. Nsd2 and its paralogs are all able to di-
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methylate H3K36 and are each catalytically dominant in different tissue types (52,102,103). We 
thus used a gene signature representing the average expression of NSD1, NSD2, and NSD3 to 
more broadly capture the consequences of increased H3K36me2 deposition on clinical outcomes. 
Upon applying this gene signature to transcriptomic databases across various carcinomas 
(104,105), we found that high expression of the signature predicted poor prognosis (Figure 2D). By 
contrast, the expression of individual members of the NSD family had substantially less predictive 
value (data not shown). These results suggest that elevated expression of writers of H3K36 di-
methylation is associated with poor clinical outcome, underscoring the importance of considering 
shared catalytic activities or molecular functions in relation to tumor behavior.   
 Tumor initiating cells (TICs) – a subpopulation of tumor cells capable of seeding and 
propagating new tumors – are commonly enriched for cells that are transcriptionally characterized 
by EMT signatures (106). Furthermore, induction of an EMT program has been shown to directly 
regulate the TIC phenotype (78). Accordingly, we found that forcing cells to be epithelial by loss of 
Nsd2 decreased their ability to form 3D tumor spheres, while locking cells in the mesenchymal 
state by loss of Kdm2a increased their sphere-forming ability, suggesting that these enzymes 
reciprocally regulate tumor initiation capacity (Figure 2E). Collectively, these findings demonstrate 
that regulators of the histone mark H3K36me2 drive attributes of tumor progression that are 
associated with poor clinical outcome.    
 
Nsd2 and Kdm2a-induced changes in epithelial plasticity have unique contributions to metastasis 
Although epithelial-mesenchymal plasticity is thought to drive metastatic dissemination, 
recent studies have called this paradigm into question (73,74,107). To investigate the contributions 
of the epithelial and mesenchymal states to metastasis, we orthotopically transplanted tumor cells 
and found that Kdm2a-deficient tumors (locked in a mesenchymal state) released more circulating 
tumor cells (CTCs) into the bloodstream compared to Cas9 control tumors (Figure 3A), which is 
consistent with their increased migratory behavior in vitro (Supplementary Figures S6A-B). 
Conversely, Nsd2-deficient tumors (locked in an epithelial state) released few CTCs into the 
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bloodstream (Figure 3A). These results support the notion that cells with a mesenchymal 
phenotype enter the bloodstream far more efficiently than cells with an epithelial phenotype. 
 While Kdm2a-deficient tumor cells readily intravasated into circulation, the resulting 
metastatic lesions found in the lungs were significantly smaller than those arising in their wild type 
counterparts (Figure 3B).To further study the effect of epithelial-mesenchymal state on metastatic 
colonization, we injected Nsd2- and Kdm2a-deficient tumor cells directly into the tail veins of mice, 
thereby bypassing the first steps of the metastatic cascade. Nsd2-deficient cells were more efficient 
than control cells at forming large lung metastases (Figure 3C), while Kdm2a-deficient cells 
remained poor colonizers (Figure 3D). Importantly, these differences in metastatic competence 
were not due to differences in tumor growth or cell proliferation (Supplementary Figures S6C-D). 
Taken together, these results demonstrate that epithelial and mesenchymal phenotypes each have 
their own distinct advantages during metastatic spread, supporting the concept that EMT and MET 
contribute at different points in the metastatic cascade and that plasticity is more important for 
effective metastasis than either the epithelial or mesenchymal state alone (3–5,108,109).  
 
Global increase in H3K36me2 is an epigenomic feature associated with the mesenchymal state 
Nsd2 and Kdm2a act antagonistically to regulate H3K36me2, strongly indicating that this 
histone mark is a key determinant of epithelial identity. To test this hypothesis, we first performed 
histone mass spectrometry to look for global changes associated with epithelial plasticity. 
Remarkably, H3K36me2 was the only histone post-translational modification (PTM) to exhibit a 
significant difference (fold change>1.5, padj<0.05) between Ecad- and Ecad+ cells across multiple 
cell lines (Figure 4A and Supplementary Figures S7A-B). In this setting, the enrichment of 
H3K36me2 in mesenchymal cells was accompanied by higher expression of Nsd2 (Figure 4B). 
Differences in global levels of H3K36me2 were readily detected by western blots of sorted Ecad+ 
and Ecad- cells (Supplementary Figure S7C), and in cultured cells (Supplementary Figure S7D) 
and PDAC tumors (Supplementary Figure S7E) stained for H3K36me2. Thus, transition to a 
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mesenchymal state is reproducibly associated with global accumulation of H3K36me2 in multiple 
in vitro and in vivo settings. 
To determine whether differences in H3K36 methylation also occur in the setting of 
experimentally induced plasticity, we treated cells with Tgf-β, a potent EMT stimulus, and again 
found that H3K36me2 was the only histone PTM to exhibit a global increase across cell lines 
(Figure 4C). Upon Tgf-β stimulation, different cell lines upregulated the expression of different 
H3K36me2 methyltransferases, each of which can contribute to the observed global increase in 
H3K36me2 (Figure 4D). Interestingly, despite overt morphological changes within 4 days of Tgf-β 
treatment (Supplementary Figure S8A), a build-up of H3K36me2 was not apparent until 15 days of 
treatment (Supplementary Figures S8B-E), suggesting that global H3K36me2 accumulation may 
be a gradual phenomenon that helps to maintain the mesenchymal phenotype. To explore this 
possibility, we withdrew Tgf-β after 4 or 15 days of treatment and assessed how long it took cells 
to revert to an epithelial state. While the effects of short-term Tgf-β treatment were readily reversible 
upon Tgf-β withdrawal, cells exposed to Tgf-β for 15 days remained mesenchymal for much longer 
(Figure 4E). Eventually, when these cells finally reverted to their original epithelial state (Figure 4E 
and Supplementary Figure S9A), their H3K36me2 levels also began returning to baseline 
(Supplementary Figure S9B), demonstrating that epigenetic plasticity accompanies phenotypic 
plasticity. Collectively, these results suggest that Tgf-β-induced EMT involves an acute phase, 
likely mediated by the early activity of EMT-TFs, and a stable “memory” phase, reinforced by a 
broader regulation of H3K36me2 levels. 
 
Upregulation of H3K36me2 is essential for EMT 
Since Tgf-β is such a powerful EMT agent, we wondered whether Nsd2-deficient cells 
would fail to respond to this stimulus. Surprisingly, Nsd2-deficient cells treated with Tgf-β exhibited 
a typical EMT response, characterized by the repression of epithelial genes and induction of 
mesenchymal genes (Figure 5A). Strikingly, EMT was still accompanied by an increase in 
H3K36me2 levels despite total absence of Nsd2 (Figure 5B). This result suggests that in the 
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presence of a strong EMT stimulus, Nsd2-deficient cells compensate by finding other ways to 
upregulate the mark, indicating that H3K36me2 accumulation itself is essential for the 
mesenchymal identity. 
In the absence of Nsd2, other enzymes can still di-methylate H3K36. In fact, upon Tgf-β 
stimulation, Nsd2 paralogs were upregulated to a greater extent in the sgNsd2 clones compared to 
the wildtype (Figure 5C), potentially explaining how Nsd2-deficient cells treated with Tgf-β can still 
generate H3K36me2 and undergo EMT. To circumvent such compensatory mechanisms and more 
directly interrogate the biological role of this histone mark, we employed a mutant form of H3.3 with 
a Lys-to-Met substitution at position 36 (K36M), which reduces the overall abundance of 
H3K36me2 by dominantly inhibiting Nsd2 and other H3K36 methyltransferases (Figure 5D and 
refs. (52,53,110). In contrast to prior observations (52,53,102), we did not observe consistent 
decreases in H3K36me1 or H3K36me3. 
Expression of H3.3K36M in cell lines from multiple tumor types, including PDAC (Panc02 
and PANC1), lung carcinoma (A549), and prostate carcinoma (DU145), was sufficient to induce an 
epithelial phenotype (Figure 5E and Supplementary Figure S10). However, in contrast to Nsd2-
deficient cells, K36M-expressing cells failed to accumulate H3K36me2 following Tgf-β treatment 
(Figure 5F) and were refractory to its EMT-inducing effects (Figures 5G-H). These results indicate 
that increased H3K36me2 is essential for stabilizing the mesenchymal state across various cancer 
types, and that failure to accumulate H3K36me2 impedes a cell’s ability to undergo EMT. 
 
Genome-wide regulation of H3K36me2 reprograms enhancers associated with master EMT 
transcription factors  
To better understand the epigenomic mechanisms by which H3K36me2 influences 
epithelial plasticity, we performed a series of ChIP-seq experiments. While loss of Nsd2 led to 
global reductions in H3K36me2, some genomic regions maintained this mark (Supplementary 
Figure S11A, boxed regions). We therefore performed separate analyses of genomic loci that 
exhibit dynamic changes in H3K36me2 (“H3K36me2-regulated”) versus loci that retain the mark 
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(“H3K36me2-stable”) in Nsd2-deficient cells. H3K36me2-regulated domains were associated with 
loss of the activating marks H3K27ac and H3K4me1 and an increase in the repressive mark 
H3K27me3 (Figure 6A and Supplementary Figure S11B, top). By contrast, these changes were not 
observed in H3K36me2-stable regions (Figure 6B and Supplementary Figure S11B, bottom). This 
suggests that dynamically regulated H3K36me2 domains encompass a subset of H3K27ac-
containing regulatory elements.  
H3K27ac is a feature of both active promoters and enhancers. Since dynamic changes in 
H3K36me2 levels are most apparent in intergenic regions (refs. 35,49,57,59 and Supplementary 
Figure S11C), we hypothesized that H3K36me2 modulates epithelial plasticity by regulating 
enhancer activity. To test this, we examined the spatial distribution of H3K36me2, analyzing 
separately genomic regions near transcriptional start sites (putative promoters) versus more distal 
elements (putative enhancers). Consistent with our hypothesis, almost all H3K36me2-regulated 
domains were in distal elements, while a more substantial fraction of H3K36me2-stable domains 
was found in promoter regions (Supplementary Figure S11D). Similarly, H3K27ac peaks lost with 
Nsd2 depletion were more likely to be found in distal elements than those that were gained or 
unchanged (Supplementary Figure S11E). In addition, we compared H3K36me2 and H3K27ac 
coverage in distal elements and promoters in the presence or absence of Nsd2. Promoter-localized 
H3K36me2 domains and H3K27ac were maintained with loss of Nsd2 (Supplementary Figure 11F, 
right panels). By contrast, most H3K36me2 domains in distal elements disappeared following Nsd2 
loss, a shift that was associated with large decreases in H3K27ac (Supplementary Figure 11F, left 
panels). These results suggest that H3K36me2-regulated domains are enriched for distal 
regulatory elements (i.e. enhancers), while H3K36me2-stable domains are enriched for promoters. 
Finally, we examined the effects of H3K36me2 on gene expression by analyzing the 
transcriptional consequences of Nsd2 loss in H3K36me2-regulated and -stable regions. Genes 
associated with H3K36me2-regulated domains exhibited reduced expression following Nsd2 loss 
compared to genes associated with H3K36me2-stable domains (Figure 6C and Supplementary 
Figure S12A). Remarkably, although H3K36me2-regulated domains were widely dispersed across 
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the genome (>10,000 peaks), we found them to be associated with relatively few genes (n=189), 
including many pro-metastatic and EMT master regulatory factors (Figure 6C and Supplementary 
Figures S12B-C). By contrast, the expression of genes associated with H3K36me2-stable domains 
was mostly unchanged or upregulated with Nsd2 loss and included markers of epithelial cell identity 
or differentiation (Figure 6C and Supplementary Figure S12B). Interestingly, H3K36me2-regulated 
and H3K36me2-stable genes are associated with distinct enhancer and promoter activities. Both 
enhancer (Figure 6D, left) and promoter (Supplementary Figure S12D, top) activities of H3K36me2-
regulated genes are directly affected by H3K36me2 levels. And, as expected, the enhancer 
activities of H3K36me2-stable genes remained largely unchanged (Figure 6D, right). However, 
while H3K36me2 levels remained unchanged with Nsd2 loss at the promoters of H3K36me2-stable 
genes, including Ecad, H3K27ac coverage still increased at these promoters (Supplementary 
Figure S13D, bottom), suggesting that transcriptional activation at these sites is independent of 
H3K36me2 levels. These results indicate that H3K36me2 influences plasticity by altering enhancer 
activity, as well as corresponding promoter activity, to regulate the transcription of key regulatory 
factors (i.e. EMT-TFs). 
 
Master EMT transcription factors act downstream of H3K36me2 activity 
 While previous studies have found that EMT-TFs like Snai1, Snai2, and Zeb1 physically 
and functionally interact with epigenetic modifiers to drive changes in gene expression (78–84), our 
analyses suggest that there is a level of epigenetic regulation upstream of EMT-TF activity. To test 
this, we overexpressed Snai1 or Zeb1 in cells lacking Nsd2 (Figure 6E). We found that either EMT-
TF was sufficient to induce an EMT transcriptional program by downregulating epithelial markers 
and upregulating mesenchymal markers (Figure 6F). In agreement with our earlier finding that Zeb1 
is the major driver of EMT in our PDAC cell lines, Snai1 was less effective than Zeb1 at rescuing 
the EMT phenotype. Interestingly, and in contrast to Nsd2 (Supplementary Figure S4), neither Zeb1 
nor Snai1 appeared important for the expression of other EMT-TFs, suggesting that the level of 
H3K36 di-methylation, rather than transcription factor crosstalk, is responsible for broad EMT-TF 
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upregulation during EMT. Finally, neither Zeb1 nor Snai1 overexpression induced the expression 
of Nsd1, Nsd2, or Nsd3 (Figure 6F) or resulted in increased H3K36me2 levels in Nsd2-deficient 
cells (Figure 6G). Collectively, these results indicate that these master regulatory factors act 



























Epithelial plasticity is associated with the activity of multiple EMT-TFs, whose expression 
levels and functions vary across different developmental, homeostatic, and malignant settings. This 
context-specific variation has complicated efforts to establish unifying principles in their mode of 
action and downstream consequences. Here, we sought to understand how epigenetic regulators 
– and their molecular targets – influence epithelial differentiation state. Until recently, the biological 
functions of specific epigenetic modifications have been inferred from gain- and loss-of-function 
studies involving their putative modifying enzymes. However, many of these marks, particularly 
those found on histones, are regulated by multiple, redundant enzymatic writers and erasers. 
Furthermore, these enzymes have non-histone substrates and/or act as scaffolds to recruit other 
factors (112). Consequently, it has been challenging to directly assess the biological impact of 
these modifications (as opposed to the enzymes catalyzing their regulation). Recently, histone 
lysine-to-methionine (K-to-M) point mutations have emerged as a powerful tool to study a subset 
of histone modifications (52,53,113,114). Accordingly, we employed the K36M histone mutant to 
directly interrogate the function of H3K36me2 in cellular plasticity and its impact on other 
epigenomic features. Our study shows that gain of the histone mark H3K36me2 in carcinoma cells 
is a conserved epigenome-wide determinant of mesenchymal identity, thereby demonstrating that 
epigenomic reprogramming is not merely a consequence of EMT but instead is actively involved in 
enforcing and/or maintaining cellular states in cancer.   
Our finding that the H3K36me2 mark is critical for reinforcing the mesenchymal state is 
consistent with work in human chondroblastoma, where mutant H3K36M acts as an oncogenic 
driver by dysregulating many of the pathways involved in normal mesenchymal differentiation 
(52,53). Similarly, loss of NSD2 is associated with Wolf-Hirschhorn syndrome (WHS), a condition 
characterized by a collection of midline phenotypes – craniofacial abnormalities, cardiac anomalies, 
and neurodevelopmental delays – indicative of defects in neural crest (115,116). EMT is essential 
for neural crest cells to leave the neural tube during development, and recent studies suggest that 
NSD2 plays a direct role in neural crest cell migration (117,118). Therefore, our finding that Nsd2 
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promotes a mesenchymal migratory phenotype in cancer may reflect an oncogenic adaptation of 
normal developmental processes involving this enzyme and its histone target, implicating the 
regulation of H3K36me2 in both physiologic and disease-related contexts. 
We found that the enzymes involved in global writing and erasing of H3K36me2 play 
dramatic and distinct roles at different stages of metastatic progression. Specifically, Nsd2 loss 
inhibits EMT, thereby reducing invasion and bloodstream entry, while Kdm2a loss inhibits MET, 
thereby reducing metastatic colonization. Neither of these perturbations influence cell proliferation 
or tumor growth, suggesting that flexibility in cellular state, rather than primary tumor size, is a major 
determinant of metastatic progression. These results join a growing body of evidence implicating 
epigenetic deregulation in metastasis (119–121), where the phenotypic plasticity afforded by 
epigenetic reprogramming may allow cells to overcome the diverse selective pressures 
encountered at distinct stages of metastatic spread. 
An inverse relationship between H3K36me2 and repressive polycomb activity has been 
proposed as a mechanism by which H3K36me2 regulates gene expression (52,53,97). While we 
also observed an inverse relationship between H3K36me2 and H3K27me3 (the target of 
polycomb), our study found that H3K27ac peaks residing within broad intergenic H3K36me2 
domains are lost when H3K36me2 levels decrease, indicating that H3K36me2 also mediates its 
effects by modulating enhancer activity. We were surprised to find that despite the global 
distribution of H3K36me2, relatively few genes (<200) were transcriptionally impacted by dynamic 
changes in this histone mark. Remarkably, this list included virtually all key EMT-TFs, as well as 
several pro-metastatic factors, including members of the Zeb, Snail, Prrx, Sox, and Smad gene 
families. Our finding that Nsd2 regulates epithelial plasticity by altering enhancer activity expands 
on previous work implicating Nsd2 in the regulation of EMT and EMT TF expression in prostate 
cancer (90–92). By contrast, genes associated with the epithelial state, including various cell 
adhesion molecules (and Ecad itself), appeared to be regulated at their promoters independently 
of dynamic changes in H3K36me2. These results support a hierarchical model of epithelial plasticity 
involving two tiers of control: a first tier in which transcriptional regulation of epithelial and 
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mesenchymal programs is achieved by the acute activity of EMT-TFs, and a higher order tier 
dependent on H3K36me2-mediated reprogramming of enhancers associated with these EMT-TFs, 
thereby achieving a more stable epigenetic memory of epithelial-mesenchymal state.  
Finally, our results have translational implications for cancer therapy. In addition to its role 
in cancer metastasis, epithelial plasticity is a major mechanism of therapeutic resistance to 
chemotherapy and targeted agents (106). However, the signaling pathways that drive EMT and 
MET are highly heterogeneous and converge on diverse transcriptional regulators, making it 
challenging to develop strategies to inhibit these processes. Our finding that H3K36me2 regulation 
is a conserved and required feature of carcinoma-associated epithelial plasticity may represent a 
way around this barrier, as the enzymes mediating this histone PTM are all potentially targetable 
with small molecules. There is growing evidence that inhibitors of epigenetic modifiers can be both 
highly specific and potent (122), paving the way for strategies to target epithelial plasticity and other 
transcriptional processes. For example, other potential targets from our screen, such as KDM1A, 
which has been shown to interact with SNAI1 to drive EMT (79), and DOT1L, which was recently 
demonstrated to regulate EMT in breast cancer (123), already have inhibitors that are currently 
being tested in clinical trials for various cancers. Nevertheless, in terms of targeting H3K36me2, 
the existence of at least five histone methyltransferases capable of catalyzing its formation – NSD1, 
NSD2, NSD3 , ASH1L, and SETMAR – suggests that redundant and/or context-dependent 










Materials and Methods 
Animals 
KrasLSL-G12D; p53L/+; Pdx1-cre; Rosa26YFP/YFP (KPCY) mice have been described previously 
(87). Female 6- to 8-week-old C57BL/6J or NOD/SCID mice were purchased from The Jackson 
Laboratory and Charles River Laboratory, respectively, for tumor cell injection experiments. All 
vertebrate animals were maintained and experiments were conducted in compliance with the 
National Institutes of Health guidelines for animal research and approved by the University of 
Pennsylvania Institutional Animal Care and Use Committee. 
 
Cell lines and culture conditions 
Murine PDAC cell lines 3077c4, 483c6, and c8 were derived from primary KPCY tumors of 
mixed genetic background (88). 6419 c5 and 6694 c2 were derived from primary tumors derived 
from KPCY mice that have been backcrossed onto the C57BL/6J mouse strain (69). The murine 
Panc02 cell line was provided by Dr. Robert Vonderheide. The human PDAC PANC1 cell line was 
provided by Dr. Anil Rustgi. The human prostate cancer cell line DU145 was provided by Dr. Irfan 
Asangani, and the human lung adenocarcinoma cell line A549 was provided by Dr. Kathryn Wellen. 
All human lines were originally obtained from ATCC. All murine lines and the PANC1 cell line were 
single cell FACS to establish clonal cell lines. 
3077 and 483 were cultured in PDEC media, as previously described (87). All other murine 
and human cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% heat-inactivated fetal bovine serum, 10% glutamine, and 150 µg/mL gentamicin at 37°C, 
5% CO2, 21% O2, and 100% humidity. Cell lines were maintained and passaged according to ATCC 
recommended procedures. Cells lines were regularly tested for mycoplasma using MycoAlert 




Plasmid construction and cloning 
For studies interrogating individual genes, sgRNA-encoding oligonucleotides were inserted 
into the pSpCas9(BB)-2A-Puro (PX459) V2.0 vector, a gift from Feng Zhang (Addgene plasmid 
#62988), using a BsmBI restriction site. The following sgRNA oligo sequences were used: 
shRNA oligonucleotides were designed using the splashRNA algorithm (124), and cloned 
into the LT3REPIR vector (a gift from Scott Lowe, and modified from the LT3GEPIR vector - 
Addgene, plasmid #111177 - such that GFP is replaced by dsRed), as previously described (125). 
Briefly, XhoI and EcoRI restriction sites were PCR-cloned onto the shRNA oligonucleotides using 
the 5’ miR-XhoI primer – TACAATACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG, the 3’ 
miR-EcoRI primer – TTAGATGAATTCTAGCCCCTTGAAGTCCGAGGCAGTAGGCA, and the 
NEBNext High-Fidelity 2x PCR Master Mix (New England Biolabs), according to manufacturer’s 
protocol. Amplified shRNA oligos and LT3REPIR vector were digested with XhoI and EcoRI and 
ligated together. The following shRNA sequences were used: 
 
sgRNA Forward Reverse 
Ecad.1 CACCGCCAGTTTCCTCGTCCGCGCC AAACGGCGCGGACGAGGAAACTGGC 
Ecad.2 CACCGCCGGGCGCGGACGAGGAAAC AAACGTTTCCTCGTCCGCGCCCGGC 
Ecad.3 CACCGGCTGACGATGGTGTAGGCGA AAACTCGCCTACACCATCGTCAGCC 
Ecad.4 CACCGCGCCTACACCATCGTCAGCC AAACGGCTGACGATGGTGTAGGCGC 
Ecad.5 CACCGGGATCCCTCCAAGGATTCCG AAACCGGAATCCTTGGAGGGATCCC 
Ecad.6 CACCGCTACGATTATCTGAACGAGT AAACACTCGTTCAGATAATCGTAGC 
Zeb1.1 CACCGTTGTAGCCTCTATCACAATA AAACTATTGTGATAGAGGCTACAAC 
Zeb1.2 CACCGATGCAAAGGTGTAACTGCAC AAACGTGCAGTTACACCTTTGCATC 
Zeb1.3 CACCGTGTCATATGACGTTCAAGCT AAACAGCTTGAACGTCATATGACAC 
Zeb1.4 CACCGATGTCATATGACGTTCAAGC AAACGCTTGAACGTCATATGACATC 
Zeb1.5 CACCGTCCGTAAGTGCTCTTTCAGG AAACCCTGAAAGAGCACTTACGGAC 
Nsd2.1 CACCGGCAGAGGCTGAACCTAAGC AAACCGCTTAGGTTCAGCCTCTGCC 
Nsd2.2 CACCGCGTTGTGTGGTAAATCAGTG AAACCACTGATTTACCACACAACGC 
Kdm2a CACCGACAGCATTGAAGATCGAACA AAACTGTTCGATCTTCAATGCTGTC 
NSD2.1 CACCGACAACGTTGGTGATTTGGTG AAACCACCAAATCACCAACGTTGTC 
NSD2.2 CACCGCGTTGGGGAGCTGATCGACG AAACCGTCGATCAGCTCCCCAACGC 
Yfp CACCGGTAGCCGAAGGTGGTCACGA AAACTCGTGACCACCTTCGGCTACC 
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shRNA Oligo Sequence 
shZeb1 #1 TGCTGTTGACAGTGAGCGAACGTACTTTTAGTTTTAGAAATAGTGAAGCCACAGATGTATTTCTAAAACTAAAAGTACGTGTGCCTACTGCCTCGGA 
shZeb1 #2 TGCTGTTGACAGTGAGCGCCTGTAGTTTGTATTAATACAATAGTGAAGCCACAGATGTATTGTATTAATACAAACTACAGTTGCCTACTGCCTCGGA 
shSnai1 #1 TGCTGTTGACAGTGAGCGCAAGCAGCATTTTGTATAGTTATAGTGAAGCCACAGATGTATAACTATACAAAATGCTGCTTATGCCTACTGCCTCGGA 
shSnai1 #2 TGCTGTTGACAGTGAGCGCACAGTTTATTGATATTCAATATAGTGAAGCCACAGATGTATATTGAATATCAATAAACTGTATGCCTACTGCCTCGGA 
shSnai2 #1 TGCTGTTGACAGTGAGCGCCCTGGTCAAGAAACATTTCAATAGTGAAGCCACAGATGTATTGAAATGTTTCTTGACCAGGATGCCTACTGCCTCGGA 
shSnai2 #2 TGCTGTTGACAGTGAGCGAACCCACTCTGATGTAAAGAAATAGTGAAGCCACAGATGTATTTCTTTACATCAGAGTGGGTCTGCCTACTGCCTCGGA 
shEcad #1 TGCTGTTGACAGTGAGCGACCGGGACAATGTGTATTACTATAGTGAAGCCACAGATGTATAGTAATACACATTGTCCCGGGTGCCTACTGCCTCGGA 
shEcad #2 TGCTGTTGACAGTGAGCGCACCATGTTTGCTGTATTCTAATAGTGAAGCCACAGATGTATTAGAATACAGCAAACATGGTATGCCTACTGCCTCGGA 
shGata6 #1 TGCTGTTGACAGTGAGCGATCCTACTTCCTCTTCTTCTAATAGTGAAGCCACAGATGTATTAGAAGAAGAGGAAGTAGGAGTGCCTACTGCCTCGGA 
shGata6 #2 TGCTGTTGACAGTGAGCGCAACCAGGAAACGAAAACCTAATAGTGAAGCCACAGATGTATTAGGTTTTCGTTTCCTGGTTTTGCCTACTGCCTCGGA 
shKlf5 #1 TGCTGTTGACAGTGAGCGACACCTGTCAGATACAACAGAATAGTGAAGCCACAGATGTATTCTGTTGTATCTGACAGGTGGTGCCTACTGCCTCGGA 
shKlf5 #2 TGCTGTTGACAGTGAGCGAGTGAACAATATCTTCATCAAATAGTGAAGCCACAGATGTATTTGATGAAGATATTGTTCACCTGCCTACTGCCTCGGA 
shElf5 #1 TGCTGTTGACAGTGAGCGACCCTGAGATACTACTATAAAATAGTGAAGCCACAGATGTATTTTATAGTAGTATCTCAGGGCTGCCTACTGCCTCGGA 
shElf5 #2 TGCTGTTGACAGTGAGCGAGAGCCCTGAGATACTACTATATAGTGAAGCCACAGATGTATATAGTAGTATCTCAGGGCTCGTGCCTACTGCCTCGGA 
 
H3F3A K36M mutation was introduced to the pcDNA4/TO-Flag-H3.3 plasmid (a gift from 
Bing Zhu, Addgene plasmid #47980) by site-directed mutagenesis. The Q5 site-directed 
mutagenesis kit (New England Biolabs) was used according to the manufacturer’s protocol with the 
following mutagenic primers: forward - GGAGGGGTGATGAAACCTCATC and reverse – 
AGTAGAGGGCGCACTCTT. Following confirmation of the point mutation by Sanger sequencing, 
the epitope-tagged H3F3A K36M was cloned into the pCDH-EF1-FHC lentiviral vector (a gift from 
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Richard Wood, Addgene plasmid #64874) for constitutive expression using NotI and BamHI 
restriction sites.   
 
Flow cytometry and fluorescence-activated cell sorting (FACS) 
Cultured tumor cells were dissociated into single cells with Hank’s based enzyme free cell 
dissociation solution (EMD Millipore) and washed in HBSS with 5% FBS and DNase I (Sigma). 
Cells were then stained with rat anti-Ecadherin (1:250, Takara, M108), followed by APC donkey 
anti-rat (1:100, Jackson Immunoresearch). For FACS, samples were filtered through a 70 µM 
strainer to form single cell suspensions. Flow cytometric analysis was performed on a LSR II flow 
cytometer (BD Biosciences) and analyzed using FlowJo software (Treestar). FACS was performed 
on a FACSAria II sorter (BD Biosciences).  
 
Epigenetic modifier CRISPR sgRNA library construction 
A list of sgRNA sequences directed against a comprehensive murine epigenetic modifier 
gene list was a gift from Scott Lowe (MSKCC), and a sgRNA list targeting the functional and 
catalytic domains of murine epigenetic modifiers was taken from a previous study (126). 
Additionally, 108 sgRNAs targeting EMT regulatory factors, 500 non-targeting sgRNAs, and 50 
sgRNAs targeting essential genes were added. In total, the library contains 4803 sgRNAs. All 
sgRNAs were designed using design principles previously reported and were filtered to minimize 
predicted off-target effects (127). sgRNAs were synthesized in a pooled format on an array platform 
(CustomArray, Inc.) and then PCR cloned into the LRG2.1 vector, a gift from Christopher Vakoc 
(Addgene plasmid #108098) using previously described methods (128). To ensure proper 
representation of sgRNAs in the pooled lentiviral plasmids, the library was analyzed by deep-
sequencing on a NextSeq500/550 (Illumina, 75 cycles High Output kit v2.0) and MAGeCK (129), 
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which confirmed that 100% of the designed sgRNAs were cloned in the LRG2.1 vector with 
relatively even read count distribution. 
 
Lentivirus production, transduction, and viral titering 
Transfection of 293Ts for lentivirus production was performed using Opti-MEM I (GIBCO), 
DNA (expression plasmid, psPAX2, and pVSVg mixed in a 4:2:1 ratio), and polyethylenimine (PEI, 
Polysciences) at a 3:1 ratio with total DNA. Recipient cells were transduced with filtered, 
unconcentrated viral supernatant in the presence of 8 µg/mL polybrene. Appropriate antibiotic 
selection (2-8 µg/mL puromycin, 10 µg/mL blasticidin) was applied for at least 72 hours. Viral titering 
for sgRNA library was done by transduction at limiting dilution and determining the GFP+% 72 
hours later using the GUAVA easyCyte HT BG flow cytometer (Millipore).        
 
Gain of function retroviral transduction 
Full length human NSD2 and E1099K NSD2 mutant pMSCV-puro expression plasmids 
were kindly provided by Irfan Asangani. Full length KDM2A (GFP-FBXL11) was a gift from Michele 
Pagano (Addgene plasmid # 126543). Full length murine Snai1 and Zeb1 were gifts from Thomas 
Brabletz and cloned into the pCW57.1 vector using AvrII/ BamHI and MluI/BamHI restriction sites, 
respectively. 293T cells were transfected using Opti-MEM I (GIBCO), DNA (expression plasmid, 
HIV gag-pol, and pVSVg mixed in a 4:2:2 ratio), and polyethylenimine (PEI, Polysciences) at a 3:1 
ratio with total DNA. Virus collection and transduction were performed as previously detailed. 
Puromycin selection (5 µg/mL) was begun 48 hours post-transduction and continued for 1 week. 
 
CRISPR-Cas9 screen 
Cas9 was introduced to the 3077 c4 cell line by transduction of the lentiCas9-Blast 
construct (a gift from Feng Zhang, Addgene plasmid #52962), and selected with 10 µg/mL 
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blasticidin. A clonal 3077 c4-Cas9 line was generated by single-cell FACS and was later transduced 
with the epigenetic modifier library at a MOI of 0.2 such that ~20% of cells were GFP positive. 210 
million cells were transduced to yield 1000x coverage of the sgRNA library in both the Ecadherin+ 
and Ecadherin- subpopulations. T0 GFP+ Ecad+ and GFP+ Ecad- samples were collected by 
FACS 3 days post-transduction. GFP+ Ecad+ and GFP+ Ecad- samples were collected at 2 weeks 
(T2weeks) and 4 weeks (T4weeks) post-transduction. Enough cells were collected to maintain at 
least 500x coverage of the sgRNA library in each sample.  
Genomic DNA was harvested using the QIAamp DNA mini kit (Qiagen), and libraries were 
constructed according to previously described protocols (130). Briefly, sgRNAs were amplified over 
18 cycles with Herculase II fusion DNA polymerase (Agilent) per manufacturer specifications with 
PCR#1 forward and reverse primers (Supplementary Table S6). Each reaction included 3 µg of 
genomic DNA, and multiple PCR reactions were run in parallel such that all extracted genomic DNA 
was used to maintain library coverage. PCR reactions were then pooled for each sample, and 5 µl 
of each pooled PCR#1 sample was used as a template for PCR#2, which added Illumina P5/P7 
adapters, barcodes, and staggers for nucleotide complexity. For PCR#2, template was amplified 
over 25 cycles with PCR#2 forward and reverse primers (Table 1), and the resulting reactants were 
column purified with the QIAquick PCR purification kit (Qiagen) and gel extracted with the QIAquick 
gel extraction kit (Qiagen). The barcoded libraries were pooled at an equal molar ratio and 
sequenced on a NextSeq500/550 (Illumina, 75 cycles High Output kit v2.0) to generate 75 bp 
single-end reads. 
MAGeCK was used for subsequent screen analysis (129). Briefly, the sequencing data 
were de-barcoded and the 20 bp sgRNA sequence was mapped to the reference sgRNA library 
without allowing for any mismatches. The read counts were calculated for each individual sgRNA 
and normalized to the non-targeting sgRNAs. Normalized read counts of sgRNAs in Ecad+ and 
Ecad- subpopulations were log2 transformed, and graphical representation was done using the R-
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package ggplot2. To exclude false positives due to off-target effects or inconsistencies in sample 
preparation, we only focused on hits for which >80% sgRNAs targeting a gene were enriched. 
 
Pancreatosphere formation assay 
 Pancreatosphere assays were performed as described by Rovira et al., 2010 (ref. 80). 
Briefly, cell lines trypsinized and dissociated into single cells. 2500 cells were suspended in 
tumorsphere media: DMEM/F-12 with 1x B-27 supplement (Gibco), 3% FBS, 100 mM B-
mercaptoethanol (Gibco), 1x non-essential amino acids (Sigma), 1x N2 supplement (Gibco), 20 
ng/ml mouse EGF (Gibco), 20 ng/ml mouse FGF-basic (Gibco), and 10 ng/ml mouse LIF (Gibco). 
Cells were plated in 6-well ultra-low attachment culture plates (Costar) and spheres were counted 
after 5 days. 5 independent wells were used per cell line. 
 
Orthotopic implantation and circulating tumor cell (CTC) analysis 
Mice were anaesthetized using continuous-flow isoflurane, and their abdomen was 
sterilized. An incision was then made over the left upper quadrant of the abdomen, and the 
pancreas was exteriorized onto a sterile field. 1.0x104 tumor cells in 50 µl sterile DMEM were 
injected into the tail of the pancreas via a 27 5/8’’ gauge needle. Successful injection was confirmed 
by the formation of a liquid bleb at the site of injection with minimal fluid leakage. The pancreas 
was then gently placed back into the peritoneal cavity, and the peritoneum and overlying skin were 
closed with 4-0 coated Vicryl violet FS-2 sutures (Ethicon). Tumors, lungs, and livers were 
harvested, weighed, and measured 4-6 weeks following implantation. 200 µl of blood was drawn 
from tumor-bearing animals via cardiac puncture with a 1 mL insulin syringe coated with 0.5M 
EDTA pH 8.0 (Gibco) to prevent coagulation and was immediately placed in a 150 mm gridded 
plate containing RBC lysis buffer (BD Biosciences). After 10 min. of lysis at room temperature, PBS 
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was added to the plate and CTCs were directly visualized on a fluorescent microscope and 
counted.  
 
Lung metastatic colonization assay 
1.0x105 tumor cells in 100 µl sterile DMEM were injected into the tail veins of mice via a 27 
5/8’’ gauge needle. After 2 weeks lungs were harvested and weighed.  
 
Scratch assay 
Cells were plated to 70% confluency in 6-well plates and grown in serum free media for 
24-48 hours. A horizontal scratch was then made in each well with a 200 µL pipette tip. Cells were 
photographed at identical points at 0, 24, and 48 hours post-scratch. Cell migration was assessed 
by measuring the area of the scratch at each time point using ImageJ. 
 
EdU analysis 
2,000 cells were seeded into each well of a 96-well plate. EdU was spiked into the media 
at 10 µM, and 2 hours later cells were fixed and permeabilized with the fixation/permeabilization 
buffer set (eBioscience) for 30 min. at room temperature. Cells were then washed, and EdU was 
labeled with Alexa Fluor 647 azide (1:2000, ThermoFisher Scientific) by a click chemical reaction 
(100mM Tris-HCl pH 8.5, 4mM CuSO4, 100mM ascorbic acid) for 30 min. at room temperature, 





100,000 cells were plated into 6-well plates and 24 hours later were treated with either citric 
acid (control) or 10 ng/mL Tgf-β (CST) over a given time course. Cells were continuously dosed 
every 3 days and were passaged in the given agents over longer time points. 
 
RNA Isolation, real-time quantitative PCR (RT-qPCR), and RNA-seq 
RNA was prepared from cultured tumor cells or sorted cells using RNeasy Mini Kit or 
RNeasy Micro Kit (Qiagen). For RT-qPCR, cDNA was generated using High-capacity cDNA 
Reverse Transcription Kit (Life Technologies). RT-qPCR analysis was performed with 
SsoAdvanced SYBR (Bio-Rad) using a CFX384 Real-Time System (Bio-Rad). Transcript quantities 
were determined using the difference of Ct method and values were normalized to the expression 
of Tbp. The following primer sequences were used: 
Murine 
Gene Forward Reverse 
Ecad CTCCAGTCATAGGGAGCTGTC TCTTCTGAGACCTGGGTACAC 
Ocln CTGTGATGTGTGTTGAGCTTTG GGCTGCTGCAAAGATTGATTAG 
Cldn12 CCTGCTGTTCGTTTGGTATTG TGATGAATAGGGCTGTGAGTAAG 
Zeb1 CTTACGGATTCACAGTGGAGAG GTGAGCTATAGGAGCCAGAATG 
Snai1 GTCTCAGAAGGGACCATGAATAA ATAGTTCTGGGAGACACATTGG 
Snai2 GCAGACCCACTCTGATGTAAAG CAGCCAGACTCCTCATGTTTAT 
Twist1 CTAGAGACTCTGGAGCTGGATAA CGCCCTGATTCTTGTGAATTTG 
Gata6 CTTACACTCACAGCCCACTTC GGGACTGTGTTGGTGTTCTT 
Klf5 CCGCTACAATTGCTTCCAAAC CGGGTTACTCCTTCTGTTGTATC 
Elf5 CGTCAGCGTGTTCAGTTTATTG GGACGTTCTCTGCTTGGTAAA 
Epcam GCGGCTCAGAGAGACTGTG CCAAGCATTTAGACGCCAGTTT 
Fn1 TCCTGTCTACCTCACAGACTAC GTCTACTCCACCGAACAACAA 
Vim CCCTGAACCTGAGAGAAACTAAC CTCTGGTCTCAACCGTCTTAATC 
Ncad AGTGGCAGGTAGCTGTAAAC TGGCAAGTTGTCTAGGGAATAC 
Nsd2 CAATGTGAGCTGGTGCTTTG ATCGGGCATCTCGATGTTTAG 
Nsd1 TCGCTCGGGAAATGGTATTG CGTTTCCGTTTCCTTGGTTTATC 
Nsd3 CGGCATACTAGCTTGGAAGAG ATTGTGATGGAGGCTGGTAAG 
Kdm2a TCAGTCCAACCTACTAACT CAGGGTCTGGTCTGTCAATTT 
Kdm2b CTACCAAGTGGACTCACCTTAC CCTCAGGGACACACTTCTTCTT 
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Col1a1 AGACCTGTGTGTTCCCTACT GAATCCATCGGTCATGCTCTC 
Foxa1 ATGAGAGCAACGACTGGAACA TCATGGAGTTCATAGAGCCCA 
Hnf1a GACCTGACCGAGTTGCCTAAT CCGGCTCTTTCAGAATGGGT 
Hnf4a CACGCGGAGGTCAAGCTAC CCCAGAGATGGGAGAGGTGAT 
Pdgfrb GACGGTGGCTACATGGATATG GGGACTCAATGTCTGCGTATT 
Fsp1 AACCTCTCTATTCAGCACTTCC TGTGGAAGGTGGACACAATTA 
Tbp AGAACAATCCAGACTAGCAGCA GGGAACTTCACATCACAGCTC 
 
Human 
Gene Forward Reverse 
ECAD CTCCCTTCACAGCAGAACTAAC CCACCTCTAAGGCCATCTTTG 
OCLN GGTTCACTTCTCCCAGTCTTTC AGACACAATCAACAGGGTTAGG 
ZEB1 CCCATCACCTCTAAACCTTTCC GGTTCTACTTGTGGCTCTTCTT 
SNAI1 ACTATGCCGCGCTCTTTC GCTGGAAGGTAAACTCTGGATTA 
SNAI2 GCGATGCCCAGTCTAGAAA GGTAATGTGTGGGTCCGAATA 
VIM CAGCTTTCAAGTGCCTTTCTG CTTGTAGGAGTGTCGGTTGTT 
EPCAM GGTGATGAAGGCAGAAATGAATG TCATCGCAGTCAGGATCATAAAG 
FN1 CCACAGTGGAGTATGTGGTTAG CAGTCCTTTAGGGCGATCAAT 
ZO1 GCAGCCACAACCAATTCATAG GAAAGGTAAGGGACTGGAGATG 
FOXA1 CCGTTCTCCATCAACAACCT TAGAGCCGTAAGGCGAGTAT 
HNF1A GACCTCCAGCTTTCCTGTATTT CGAAGTAGCCTTCCCAGTAGA 
HNF4A GGAGAGGACAAGATGGGTAAAC TAAGACAGTGCCTGGGAGTA 
NCAD GAGGGCACATGCAGTAGATATT AACTCAGGTCTGTTGTCATTCA 
PDGFRB GCTCACCATCATCTCCCTTATC CTCACAGACTCAATCACCTTCC 
COL1A1 CCTGTCTGCTTCCTGTAAACTC GTTCAGTTTGGGTTGCTTGTC 
NSD2 TAAGCGCTGTGTGGTAACTC GGAAACCTCGGCTCTCAAATA 
TBP CCACTCACAGACTCTCACAAC CTGCGGTACAATCCCAGAACT 
  
Sequencing libraries were generated using the NEB Next Ultra RNA Library Prep kit and 
sequenced in technical duplicates on an Illumina HiSeq platform to generate 150bp paired-end 
reads (GSE137382) by Novogene (Beijing, China). Reads were aligned to the mm10 reference 
genome using STAR (v2.5.1) (132), and raw counts of gene transcripts were obtained using 
featureCounts (133), both with default settings. The raw count matrix was subsequently imported 
into R-studio and used as input for DESeq2 (134) for normalization and differential gene expression 
39 
 
analysis. Salmon was used in parallel to normalize and quantify gene expression in transcripts per 
million (TPM) through quasi-alignment. To generate ranked gene lists for pre-ranked gene set 
enrichment analysis (GSEA) (http://www.broad.mit.edu/gsea/) genes were ranked by their 
DESeq2-derived Wald statistic. The gene signatures for Squamous and Progenitor subtypes were 
derived from (101). Briefly, the top 500 and bottom 500 protein-coding genes of each subtype were 
identified from RNA-seq data derived from patient samples (98), and used to define each subtype’s 
gene signature.  
 
ATAC-seq and analysis 
Library construction - ATAC-seq samples were prepared by sorting 50,000 Ecad+ and 
50,000 Ecad- subpopulations from three clonal cell lines. The libraries were prepared as previously 
described with minor modifications (135). Briefly, nuclei were isolated from sorted cells using a 
solution of 10 mM Tris-HC pH 7.4, 10 mM NaCl, 3 mM MgCl2, and 0.1% IGEPAL CA-630. 
Immediately following nuclei isolation, the transposition reaction was conducted using Tn5 
transposase and TD buffer (Illumina) for 45 min. at 37oC. Transposed DNA fragments were purified 
using a Qiagen MinElute Kit, barcoded with primers based on Illumina TruSeq indices (Table 2), 
and PCR amplified for 11 cycles using NEBNext High Fidelity 2x PCR master mix (New England 
Biolabs). Libraries were purified by extraction from a 6% TBE gel, followed by column purification 
with the Qiagen PCR Cleanup kit. Sequencing was performed on biological triplicates using a 
HiSeq2500 (Illumina) on rapid run mode to generate 50bp paired end reads (GSE137520).   
 Analysis – After adapter trimming with cutadapt, reads were aligned to the mouse 
reference genome (GRCm38, May 23 2014), which was downloaded from the UCSC repository, 
by Bowtie2 (136). Picard was used to identify and discard reads that aligned to the mitochondrial 
genome, as well as reads mapping to multiple genomic loci were discarded from downstream 
analyses by Picard (Broad Institute). MACS2 with ‘-p 1e-7–nolambda–nomodel’ was applied on 
each ATAC-seq replicate separately to identify accessible chromatin. Peaks were subsequently 
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merged using BEDTools (137) and ATAC-seq read counts were calculated in the merged peaks 
for every replicate. The resulting count table was used to identify differentially accessible loci with 
DESeq2 in R-studio, which were then associated with their putative target genes by GREAT (138). 
The GREAT algorithm associates genomic regions with genes by defining a ‘regulatory domain’ for 
each gene in the genome, then computes ontology term enrichments using a binomial test. 
Visualization of these loci was achieved by uploading the reads-per-million-aligned-read-
normalized bigwig files to Integrative Genomics Viewer (139).  
 
ChIP and ChIP sequencing 
For ChIP, ~2x107 cells were crosslinked with 1% formaldehyde for 10 min. at room 
temperature, followed by quenching with 125 mM glycine for 5 min. at room temperature. They 
were then washed with PBS and lysed with nuclei isolation buffer. Samples were sonicated with a 
Diagenode Bioruptor at high intensity setting for 15 5 min. cycles of 30 sec on/off., to yield ~300bp 
fragments. After high-speed centrifugation, soluble chromatin from Drosophila S2 cells was spiked 
in at 2.5% of the mouse chromatin. The mixed soluble chromatin was diluted 10x and pre-cleared 
with magnetic protein A Dynabeads (Invitrogen). Immunoprecipitation with anti-H3K36me2 (CST, 
2901S), anti-H3K27me3 (CST, 9733S), anti-H3K27ac (Abcam, ab4729), anti-H3K4me1 (Abcam, 
ab8895), or rabbit IgG Isotype (Abcam, ab171870) was performed overnight at 4°C with rotation, 
with 10% kept as input DNA. Immunocomplexes were recovered with magnetic Protein A 
dynabeads and washed sequentially using a low salt buffer, a high salt buffer, Lithium Chloride 
buffer, and TE buffer. Samples were eluted twice with sodium bicarbonate. Eluted ChIP DNA was 
treated with RNase A (0.2 mg/mL) overnight at 65°C, then incubated with Proteinase K (0.2 mg/mL) 
for 2 hours at 45°C. DNA samples were purified using QIAquick PCR Purification Kit (Qiagen). For 
ChIP sequencing, libraries were prepared according to the NEBNext Ultra II DNA Library Prep Kit 
(New England Biolabs) protocol, using barcoded primers from NEBNext Multiplex Oligos Index 
Primers Sets 1 and 2. Libraries were pooled and sequenced in technical duplicates on the 
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Sequencing reads were aligned to the mouse (GRCm38, May 23 2014) and the drosophila 
melanogaster reference genomes (dm6, August 2014) using STAR (v2.5.1) with default settings. 
Duplicate and low-quality reads (PHRED score <30) reads were removed using SAMtools (140). 
The normalization factor was determined from the drosophila reads as previously described (141). 
The bam files were converted to ChIPRX-normalized bigwig tracks using deepTools (142). 
Single-end reads were extended up to the fragment length (200 bp) along the read direction. 
Enrichment peaks were called with MACS2 with default settings (H3K27ac and H3K4me1) and 
broad settings (H3K36me2 and H3K27me3). Blacklisted peaks 
(https://sites.google.com/site/anshulkundaje/projects/blacklists), were excluded in all subsequent 
analysis. To identify peaks differentially bound between WT and sgNsd2 samples we first identified 
the consensus peak set that includes the unique set of peaks enriched across both samples. 
Differentially bound peaks were then identified using DESeq2 with the ChIPRX normalized tag 
counts at the consensus peak regions as input and only peaks with adjusted p-value <0.001 were 
used for further analysis. Overlap analysis of peaks was performed using an in-house python script 
and peaks were annotated using HOMER (http://homer.ucsd.edu/homer/ngs/annotation.html). 
 
Immunofluorescence and Hematoxylin & Eosin (H&E) staining 
Tissues were fixed in Zinc-formalin and embedded in paraffin for histological analysis and 
immunofluorescence staining. Sections were deparaffinized, rehydrated, and prepared by antigen 
retrieval. For cell lines, cells were seeded into 8-well Nunc Lab-Tek II chamber slides (Thermo 
Scientific) and fixed in 4% paraformaldehyde for 15 mins. For immunofluorescence staining, 
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sections or fixed cells were blocked in PBS with 0.3% Triton-X and 5% donkey serum for 1 hour, 
stained with primary and secondary antibodies, and mounted with Aqua Polymount (Polysciences, 
Inc). Primary antibodies used include goat anti-GFP (Abcam, ab6673), rat anti-E-cadherin (Takara 
Bio, M108), and rabbit anti-H3K36me2 (Abcam, ab9049). Slides were visualized using an Olympus 
IX71 inverted multicolor fluorescent microscope equipped with a DP71 camera. Images were 
quantified using ImageJ software. 
For H&E staining, sections were deparaffinized, rehydrated, stained with hematoxylin, 
differentiated with acidic ethanol, stained for eosin, dehydrated, and mounted with Permount. Slides 
were visualized using the Keyence BZ-X710 all-in-one fluorescence microscope.  
 
Histone extraction 
Histones were acid extracted according to standard protocols. Briefly, nuclei were isolated 
from cells lysed with a hypotonic lysis buffer. Histones were extracted from the nuclei with 0.2N 
H2SO4, precipitated in 33% trichloroacetic acid (TCA), washed with acetone, and resuspended in 
diH2O.   
 
Immunoblotting 
For whole cell lysates, cells were washed with cold PBS and lysed in RIPA lysis buffer. 
Extracted histones or whole cell lysates were separated by SDS-PAGE, transferred to PVDF 
membrane, blocked in 5% non-fat milk in PBS plus 0.1% Tween-20, probed with primary 
antibodies, and detected with horseradish peroxidase-conjugated secondary antibodies (Jackson 
Immunoresearch). Primary antibodies used include: anti-H3 (CST, 9715S); anti-H3K36me2 (CST, 
2901S); anti-H3K36me3 (Abcam, ab9050); anti-H3K36M (Millipore, ABE1447); anti-Nsd2 
(Millipore, MABE191); anti-Kdm2a (Abcam, ab191387); anti-alpha tubulin (CST, 3873S); anti-E-




Histone derivatization, mass spectrometry, and PTM quantification 
Derivatization - Histones were derivatized according to standard protocol (143). Briefly, 5-
10ug of acid-extracted histones were resuspended in 100mM ammonium bicarbonate (pH 8.0) and 
mixed with freshly prepared propionic anhydride with acetonitrile for 15 min. at 37 °C. Histones 
were then digested with trypsin (enzyme: sample ratio 1:20) overnight at 37 °C. The peptides were 
then desalted and stored dried. They were resuspended in 0.1% formic acid just before mass 
spectrometry. 
Direct injection–MS - Samples were placed in a TriVersa NanoMate (Advion) and acquired 
either manually or by using a sequence coordinated with MS acquisition by a contact closure. The 
NanoMate was set up with a spray voltage of 1.7 kV and a gas pressure of 0.5 psi. Samples were 
acquired in the Orbitrap Fusion Tribrid (Thermo Scientific). All scans were acquired in the orbitrap, 
at 240,000 resolution for the full MS and at 120,000 resolution for MS/MS. The AGC target for the 
tSIM-MSX scans was set to 10E6. The full description of the DI-MS acquisition method has been 
previously described (144). 
Histone peptide quantification - Raw files were searched with a modified version of the 
software EpiProfile 2.0 (145). Histone peptides are collected in MS scans, and isobaric peptides 
are collected in targeted pre-set MS/MS scans. The software reads the intensities from MS scans 
to calculate the percentage of all peptides with the same amino acid sequence. The unique 
fragment ions in the MS/MS scans are extracted to discriminate isobaric peptide intensities from 
the MS scans. The software EpiProfileLite is available on GitHub at 





Comparisons between two groups were performed using Students’ unpaired t test. The 
Holm Sidak correction for multiple testing was applied where indicated. All statistical analyses were 
performed with Graphpad Prism 7 and 8 (GraphPad). Error bars show standard error of the mean 
(SEM), as indicated in the legends, and p<0.05 was considered statistically significant. * indicates 
p<0.05, ** p<0.01, *** p< 0.001, and **** p< 0.0001 unless otherwise indicated. ns denotes not 
significant. For sequencing experiments, DESeq2 (134) used to generate adjusted p-values (FDR). 
And for TCGA survival analysis, KM plotter (105) was used to generate logrank P-values. 
 
Data Resources 
All sequencing data has been deposited in GEO under the series GSE137523, which 




PRISM software was used for the statistical analysis and data visualization 
(http://www.graphpad.com). The R language and environment for statistical computing and 
graphics (https://www.r-project.org) was utilized in this study for the statistical and bioinformatics 
analysis of RNA-seq, ATAC-seq, and genome-seq data. The R packages used for the analysis 
described in the method section were obtained from the Bioconductor 









Figure 1: An epigenetic modifier-focused CRISPR-Cas9 screen identifies Nsd2 and Kdm2a 
as reciprocal regulators of epithelial-mesenchymal differentiation. (A) Flow cytometry scheme 
for quantifying or sorting epithelial and mesenchymal subpopulations from clonal mouse pancreatic 
ductal adenocarcinoma (PDAC) cell lines. Epithelial subpopulations are identified by positive 
surface E-cadherin staining (Ecad+, outlined in red), while mesenchymal subpopulations are 
identified by the absence of surface E-cad (Ecad-). (B) Heatmap summarizing triplicate qPCR 
experiments on sorted Ecad- and Ecad+ subpopulations for each of 3 cell lines. Increase and 
decrease in Ecad-/Ecad+ log2fold change is shown in purple and green, respectively. (C) 
Representative ATAC-seq tracks of sorted Ecad- and Ecad+ subpopulations from 3 cell lines, 
shown in purple and green, respectively. Statistically significant (padj<0.1) enrichment peaks are 
boxed. Arrow indicates relationship between the Zeb2 promoter and a putative distal regulatory 
element. (D) Summary of plasticity experiments performed on 4 cell lines. Sorted Ecad- and Ecad+ 
subpopulations were replated and passaged over the course of 4 weeks. Samples were 
reassessed for Ecad+% by flow cytometry every 2 weeks. Data are means ± SEM from biological 
replicates (n=3). Dotted lines represent the Ecad+% of the bulk, unsorted parental population of 
each cell line. (E) Experimental outline for focused CRISPR screen. See materials and methods 
for a full description. (F) sgRNA representation in Ecad- (x-axis) and Ecad+ (y-axis) populations as 
log2-transformed normalized read counts. (G-H) Top: Representative Ecad flow histograms for 
clones expressing sgNsd2 (G)and sgKdm2a (H) compared to Cas9-only wildtype (WT) controls, as 
well as IgG-staining control for 3 cell lines. Bottom: Corresponding Western blots of cell lysates 
(top panels) and acid-extracted histones (bottom panels) with antibodies against the indicated 
proteins. (I-J) Western blots of cell lysates (top panels) and acid-extracted histones (bottom panels) 
of Cas9-only wildtype (WT) controls and sgNsd2 (I) and sgKdm2a clones (J) expressing empty 






Figure 2: Nsd2 and Kdm2a have reciprocal effects on tumor differentiation and tumor 
initiation. (A) Gene set enrichment analyses (GSEA) of WT versus sgNsd2 (left) or sgKdm2a 
(right) RNA-seq using the EMT Hallmark signature. Normalized enrichment score (NES) and false 
discovery rate (FDR) are shown alongside. (B) GSEA plots evaluating the Bailey squamous and 
progenitor signatures upon loss of Nsd2 (left) or Kdm2a (right). (C) Representative in vitro 
brightfield (BF, left) and in vivo immunofluorescent (IF, right) images of orthotopic tumors derived 
from cell lines with the indicated genotypes. Co-staining for Ecad (red), YFP (yellow), and DAPI 
(blue). Scale bars = 100µm. (D) Kaplan-Meier plots of overall survival (OS) or relapse-free survival 
(RFS) of patients, stratified by high (red) or low (black) expression of a gene signature that 
represents the average expression level of NSD1, NSD2, and NSD3. Median expression of this 
gene signature was used as the cutoff. RNA-seq and clinical data was obtained from the KM plotter 
database and includes datasets deposited in TCGA and GEO (104). P-value was calculated by log 
rank test. (E) Number of pancreatospheres formed from 2,500 cells of the indicated cell lines and 
genotype (n=5 technical replicates, error bars indicate SEM). Statistical analysis by Student’s 












Figure 3: Nsd2 and Kdm2a mediate reciprocal effects on metastatic progression. 
(A) Quantification of CTCs/200µl blood from mice harboring orthotopic tumors from cell lines with 
the indicated genotypes. For Cas9 controls, n=4-5 mice/cell line. For sgNsd or sgKdm2a, n=2 
clones/genotype, n=3-5 mice/clone. (B) Representative IF images (left) and quantification (right) of 
macrometastatic foci (≥ 100 cells) in lungs of mice bearing orthotopic tumors. Percentages of 
Ecad+YFP+ tumor cells out of total YFP+ tumor cells are indicated in white. Co-staining for Ecad 
(red), YFP (green), and DAPI (blue). (C-D) Representative H&E images and quantifications of 
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pulmonary metastatic burden 14 days after tail vein injection of sgNsd2 (C) and sgKdm2a (D) cells; 
pulmonary metastatic burden was determined by both lung/body mass ratio and number of lung 
nodules per section. For Cas9 controls, n=4-5 mice/cell line. For sgNsd or sgKdm2a, n=2 
clones/genotype, n=4-5 mice/clone. Statistical analysis by Student’s unpaired t-test with 





















Figure 4: Upregulation of H3K36me2 is associated with the mesenchymal state.  
(A) Volcano plot presenting log2-transformed p-value and fold change of histone H3 and H4 single 
post-translational modification (PTM) relative abundance derived from mass spectrometry for 
Ecad- vs. Ecad+ sorted cells. Two variants for histone H3, the canonical H3.1 and non-canonical 
H3.3, which are both known to accumulate K36me2, are shown. Horizontal dotted line demarcates 
Student’s unpaired t-test p-value < 0.05, while vertical dotted lines demarcate ± 1.5-fold change 
(n=3 cell lines). H3K36me2 marks are labeled and represented in purple. When Holm Sidak 
correction for multiple testing is applied, Padj=0.05 (H3.1K36me2) and 0.028 (H3.3K36me2). (B) 
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Relative mRNA expression of Nsd1, Nsd2, and Nsd3 in sorted Ecad+ (green) and Ecad- (purple) 
cells. Results from 3 different cell lines are shown. Bars represent mean ± SEM. (C) Volcano plot 
presenting log2-transformed p-value and fold change of histone H3 and H4 single post-translational 
modification (PTM) relative abundance derived from mass spectrometry for cells undergoing 15 
days of Tgf-β treatment vs. citric acid control. Horizontal dotted line demarcates Student’s unpaired 
t-test p-value < 0.05, while vertical dotted lines demarcate ± 1.5-fold change (n=3 cell lines). When 
Holm Sidak correction for multiple testing is applied, Padj=0.00001 (H3.1K36me2 and 
H3.3K36me2). (D) Relative mRNA expression of Nsd1, Nsd2, and Nsd3 in cells treated with Tgf-β 
for 15 days. Results from 3 different cell lines are shown. Bars represent mean ± SEM. (E) 
Normalized mean fluorescence intensity (MFI) of Ecad in control cells and cells treated with Tgf-β 
for 4 or 15 days, followed by withdrawal of Tgf-β for the number of days indicated on the x-axis. 
MFI for the 4 and 15-day treated samples were normalized to their respective controls. Experiments 














Figure 5: Upregulation of H3K36me2 is essential for EMT. (A) Relative mRNA expression of 
epithelial genes (left) and mesenchymal genes (right) in WT and sgNsd2 clones, with or without 15 
days of Tgf-β treatment, as determined by qPCR (n = 3, mean ± SEM). (B) Western blots of acid-
extracted histones from WT and sgNsd2 clones, with or without 15 days of Tgf-β treatment. (C) 
Relative mRNA expression of Nsd1, Nsd2, and Nsd3 in WT and sgNsd2 clones, with or without 15 
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days of Tgf-β treatment, as determined by qPCR (n = 3, mean ± SEM). (D-E) Western blots of acid-
extracted histones (D) and BF images (E) from cell lines expressing WT or K36M H3F3A (scale 
bars = 100µm). Fold change increases in Ecad mRNA expression in K36M samples were 
determined by qPCR (see Supplementary Figure S11) and indicated in yellow. (F-H) Western blots 
of acid-extracted histones (F), BF images (scale bars = 100µm) (G), and relative mRNA expression 
of epithelial genes (left) and mesenchymal genes (right) (H) from cells expressing WT or K36M 
H3F3A, with or without 15 days of Tgf-β treatment. mRNA expression was determined by qPCR (n 




















Figure 6: Changes in H3K36me2 levels reprogram enhancers associated with master EMT 
regulatory factors. (A-B) Aggregate plots and heatmaps of ChIP signal of the indicated histone 
marks in WT and sgNsd2 samples, centered around H3K36me2 peaks that are lost with sgNsd2 
(i.e. H3K36me2-regulated, n=10312 total peaks) (A) and H3K36me2 peaks that are not lost with 
sgNsd2 (i.e. H3K36me2-stable, n=13575 total peaks) (B). (C) Boxplots of log2fold change of mRNA 
expression of genes associated with H3K36me2-regulated peaks (n=189 genes) and H3K36me2-
stable peaks (n=690 genes). Examples are listed below each group. (D) Aggregate plots comparing 
the average ChIP signal of the indicated histone marks in WT (grey) and sgNsd2 (green) samples 
centered around putative enhancers, defined here as H3K27ac peaks that are more than +/- 2.5kb 
outside of TSS. (E) Western blots of cell lysates from sgNsd2 cells expressing dox-inducible Zeb1 
or Snai1 expression vectors. Cells were treated with dox for 4 days or left untreated. (F) Relative 
mRNA expression of epithelial markers, EMT-TFs, mesenchymal markers, and H3K36me2 
methyltransferases (left) and flow plots of Ecad staining (right) in sgNsd2 cells expressing dox-
inducible Zeb1 (top) or Snai1 (bottom) expression vectors. Cells were treated with dox for 4 days 
or left untreated. Bars represent mean ± SEM. Statistical analysis by Student’s unpaired t-test with 
significance indicated (*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001). (G) Western blots of 
acid-extracted histones from WT and sgNsd2 cells expressing dox-inducible Zeb1 or Snai1 












Graphical Summary: The global regulation of H3K36me2 via Nsd2 and Kdm2a leads to alterations 
in the activity of enhancers associated with master EMT transcription factors, which drive EMT-










Supplementary Figure S1: Establishing cell lines as tools to study epithelial plasticity. 
(A) Gating strategy and representative flow plots for 3 clonal KPCY cell lines: 3077 c4, 3077 c2, 
and 7591. First, single cells were gated using FSC-A and FSC-H. Then, cellular debris was 
excluded by FSC-A and SSC-A. Live cells were selected as DAPI-negative and YFP-positive 
events, and subsequently analyzed for E-cadherin positivity by APC-staining. IgG was used as a 
control to determine Ecad- and Ecad+ gates. (B) GO Biological Process and MSigDB Pathway 
analyses performed on ATAC-seq peaks differentially open in Ecad- samples using GREAT. In 
total, 60000 ATAC-seq peaks were identified, of which 1049 are differentially open in the Ecad- 




Supplementary Figure S2: Identifying EMT TFs as controls for screen. (A) Knockdown 
efficiencies of dox-inducible shRNAs targeting Zeb1, Snai1, and Snai2 in cell line 3077 c4 were 
determined by qPCR analysis (n = 3, mean ± SEM). Two shRNAs were tested per gene. (B-C) 
Representative flow histograms (B) and quantification (C) of Ecad+ cells in 3077 c4 expressing the 
indicated dox-inducible shRNAs (n = 3, mean ± SEM). IgG was used to determine Ecad- and Ecad+ 







Supplementary Figure S3: Comparison of H3K36 methyltransferases and demethylases in 
PDA cells. (A) Scatterplot showing enrichment of indicated sgRNAs in Ecad- (x-axis) and Ecad+ 
(y-axis) populations as log2-transformed normalized read counts of the CRISPR screen. (B) 
Scatterplots showing enrichment of ribosomal protein sgRNAs at T0 (x-axis) and T2 (y-axis) 
timepoints as log2-transformed normalized read counts in Ecad- (left) and Ecad+ (right) sorted 
populations. (C-D) Plot of indicated H3K36me2 methyltransferases (C) and demethylases (D) by 
log10-transformed p-value at 2-weeks of the CRISPR screen. (E-F) Scatterplots showing 
enrichment of indicated H3K36me2 methyltransferase (E) and demethylase (F) sgRNAs in Ecad- 
(x-axis) and Ecad+ (y-axis) populations as log2-transformed normalized read counts of the CRISPR 
screen. (G) Boxplots of the gene expressions of known H3K36me2 methyltransferases (left) and 
demethylases (right) in transcripts per million (TPM) in KPCY-derived tumor cells. Statistical 















Supplementary Figure S4: EMT-related genes are reciprocally regulated by Nsd2 and 
Kdm2a. (A-B) Boxplots of expressions of various epithelial (top) and mesenchymal (bottom) genes 
in transcripts per million (TPM) in WT versus sgKdm2a cells (A), as well as in WT versus sgNsd2 
cells (B). (C-D) Relative mRNA expression of epithelial and mesenchymal genes (qPCR) in WT 
versus sgKdm2 cells (C) and WT versus sgNsd2 cells (D). For all experiments, n=2 cell 




Supplementary Figure S5: Reciprocal transcriptomic rewiring associated with loss of Nsd2 
and Kdm2a. (A-B) Gene set enrichment analysis of genes differentially expressed in sgNsd2 
versus WT cells and in sgKdm2a versus WT cells using the HALLMARK (A) or C2 curated gene 
sets (B). Top 10 ranked gene sets are shown, with those identified in both sets of genetic 
comparisons labeled in red. (C) GO Biological analyses performed on genes differentially up or 





Supplementary Figure S6: Effects of loss of Nsd2 and Kdm2a on tumor progression. 
(A) Quantification of wound closure 48 hours post-scratch. (B) Representative images of scratch 
assays. Dotted yellow lines highlight the boundaries of each scratch. (C) Mass of orthotopic tumors 
4 weeks after implantation. (D) Quantification of EdU staining 2 hours post-EdU pulse in vitro. Each 
symbol represents a single mouse (A) or experimental replicate (B, C); square=c1, triangle=c2, 






Supplementary Figure S7: Higher global levels of H3K36me2 are found in sorted Ecad- cells. 
(A-B) Heatmaps of z-scores (A) or ratios (B) of mass spectrometry-derived histone H3 and H4 
single PTM relative abundances of sorted Ecad+ and Ecad- subpopulations with triplicates. Cell 
lines used are indicated. (C) Western blot of acid-extracted histones from sorted Ecad+ and Ecad- 
cells of 3 clonal cell lines. Flow histograms confirming purity of each sorted subpopulation are 
shown below. (D) Representative IF image (left) and ImageJ-based quantification of H3K36me2 
fluorescence intensities (right) of cultured cells from a KPCY-derived cell line (n=4 cell lines) co-
stained for E-cadherin (red) and H3K36me2 (green). White dotted lines outline cell membranes. 
Total number of cells used in the analysis are indicated. Error bars indicate SEM. p-value is Holm-
Sidak corrected. (E) Representative IF image (left) and ImageJ-based quantification of H3K36me2 
fluorescence intensities (right) of a KPCY tumor (n=5 tumors, 40 fields examined) co-stained for 
YFP (red), E-cadherin (cyan), and H3K36me2 (green). White arrow indicates a YFP+ tumor cell 
that has delaminated from epithelial structures and has lost surface Ecad staining. Total number of 






Supplementary Figure S8: Long-term Tgf-β treatment is associated with more global 
H3K36me2. (A) Representative BF images of cultured cells treated with citric acid control or Tgf-β 
for 4 days (scale bars = 100μm). (B) Western blot of acid-extracted histones from 2 cell lines treated 
with citric acid or Tgf-β for either 4 or 15 days. (C) Volcano plots presenting log2-transformed p-
value and fold change of histone H3 and H4 single PTM relative abundance for 4 days of Tgf-β 
treatment/citric acid control. Horizontal dotted line demarcates student’s unpaired t-test p-value < 
0.05, while vertical dotted lines demarcate ± 1.5 fold change (n=3 cell lines). H3K36me2 marks are 
labeled and represented in purple. (D-E) Heatmaps of z-scores (D) or ratios (E) of mass 
spectrometry-derived histone H3 and H4 single PTM relative abundances of indicated cell lines 


















Supplementary Figure S9: Tgf-β-induced transcriptional and epigenetic changes are 
reversible. (A) Relative mRNA expression of epithelial, mesenchymal, and epigenetic genes 
determined by qPCR in 2 cell lines treated with Tgf-β for 0, 4, and 15 days, followed by withdrawal 
of Tgf-β for 15 days. Error bars indicate SEM. (B) Western blot of acid-extracted histones from a 





Supplementary Figure S10: H3K36M induces transcriptional changes associated with an 
MET. Relative mRNA expression of epithelial and mesenchymal genes determined by qPCR in 










Supplementary Figure S11: Loss of H3K36me2 is associated with loss of distal H3K27ac.  
(A) Representative H3K36me2 ChIP-seq tracks of WT (grey) and sgNsd2 (green) samples over a 
segment of chromosome 2. Examples of regions where H3K36me2 signal is relatively unaffected 
with sgNsd2 are framed by solid boxes. (B) Aggregate plots comparing the average ChIP signal of 
the indicated histone marks in WT (grey) and sgNsd2 (green) samples centered around gene 
transcription start sites (TSS). (C) Genomic distribution of all H3K36me2 peaks in WT Cas9 and 
sgNsd2 cells. (D) Distribution of H3K36me2 peaks that are lost with sgNsd2 (H3K36me2-regulated) 
and those that are not lost with sgNsd2 (H3K36me2-stable) in putative promoter regions (within +/- 
2.5kb of TSS, blue) and distal elements (more than +/- 2.5kb outside of TSS, orange). (E) 
Distribution of H3K27ac peaks that are lost with sgNsd2, gained with sgNsd2, or unchanged in 
putative promoter regions (blue) and distal elements (orange). (F) Aggregate plots comparing the 
average H3K36me2 (top) and H3K27ac (bottom) ChIP signal in WT (grey) and sgNsd2 (green) 
samples over putative promoters (within +/- 2.5kb of TSS, right) and distal elements (more than +/- 














Supplementary Figure S12: EMT-related transcriptional reprogramming occurs by 
H3K36me2-dependent and -independent mechanisms. (A) Flow chart depicting integrated 
analysis of ChIP-seq and RNA-seq datasets. (B) GO Biological term enrichment performed on 
genes determined to be H3K36me2-regulated (n=189 genes, top) and genes that are H3K36me2-
stable (n=690 genes, bottom). Enrichment was performed using the Gorilla web tool (http://cbl-
gorilla.cs.technion.ac.il). (C) Representative H3K36me2, H3K27ac, and H3K4me1 ChIP-seq and 
RNA-seq tracks of WT (grey) and sgNsd2 (green) samples. Examples of putative Zeb2 and Snai1 
promoters (dotted boxes) and enhancers (solid boxes) whose decrease in activity is associated 
with a decrease in H3K36me2 signal are framed and magnified.  
(D) Aggregate plots comparing the average ChIP signal of the indicated histone marks in WT (grey) 
and sgNsd2 (green) samples centered around promoters, defined here as H3K27ac peaks that are 


















Note: italicized = stagger sequence; bold = barcode sequence 
 













PCR #1 forward AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG 
PCR #1 reverse CTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTCTTTCC 
Sample PCR #2 forward primer sequence 
T0 Ecad+  AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTACGATCGATTCCTTGGTTCTTGTGGAAAGGACGAAACACCG 

















Table 2: Primers used for ATAC-seq libraries. 











Sample Primer Sequence 



































CHAPTER 3: Epigenetic and transcriptional control of the epidermal growth factor 
receptor (EGFR) regulates the tumor immune microenvironment 
 
Abstract 
Although immunotherapy has revolutionized cancer care, patients with pancreatic ductal 
adenocarcinoma (PDA) rarely respond to these treatments, a failure that is attributed to poor 
infiltration and activation of T cells in the tumor microenvironment (TME). We performed an in vivo 
CRISPR screen and identified lysine demethylase 3A (KDM3A) as a potent epigenetic regulator of 
immunotherapy response in PDA. Mechanistically, KDM3A acts through Krueppel-like factor 5 
(KLF5) and SMAD family member 4 (SMAD4) to regulate the expression of the epidermal growth 
factor receptor (EGFR). Ablation of KDM3A, KLF5, SMAD4, or EGFR in tumor cells altered the 
immune TME and sensitized tumors to combination immunotherapy, while treatment of established 
tumors with an EGFR inhibitor erlotinib prompted a dose-dependent increase in intratumoral T cells. 
This study demonstrates an epigenetic-transcriptional mechanism by which tumor cells modulate 
their immune microenvironment and highlights the potential of EGFR inhibitors as immunotherapy 











Immune checkpoint blockade (ICB) has impacted cancer care for multiple malignancies, 
including melanoma, non-small cell lung cancer, and renal cell carcinoma (146,147). Nevertheless, 
only a fraction of patients has potent and durable responses to ICB-based immunotherapy. 
Moreover, many cancer types, including pancreatic ductal adenocarcinoma (PDA), exhibit 
negligible responses to ICB in the absence of microsatellite instability (146–148). This poor 
response has been attributed to immunosuppressive conditions in the tumor microenvironment 
(TME), including the scarcity and dysfunction of infiltrating CD8 T cells, as increased abundance 
and activity of pre-existing tumor infiltrating CD8 T cells enhances immunotherapy across different 
types of cancer (146,149–151). It has become increasingly clear that tumor cells play a central role 
in establishing a permissive immune TME by releasing secreted factors that can actively drive the 
exclusion of T cells and resistance to immunotherapy (152–154). Although several cancer cell 
intrinsic pathways have been reported to influence the composition of the immune TME 
(15,19,155–162), the key genetic and epigenetic drivers of this process remain largely unknown. 
 In the present study, we performed a targeted in vivo CRISPR screen and identified lysine 
demethylase 3A (KDM3A) as a potent epigenetic regulator of the immune TME. Cancer cells 
lacking KDM3A gave rise to tumors with marked alterations in lymphoid and myeloid infiltration and 
profound improvements in their response to combination immunotherapy. Unbiased molecular 
profiling suggested that KDM3A acts through Krueppel-like factor 5 (KLF5) and SMAD family 
member 4 (SMAD4) to regulate the expression of the epidermal growth factor receptor (EGFR), 
and functional studies revealed that ablation of tumor cell intrinsic KLF5, SMAD4, or EGFR resulted 
in increased T cell infiltration and improved immunotherapy responsiveness in previously-refractory 
tumors. Moreover, treatment of established tumors with an EGFR inhibitor erlotinib was sufficient 
to promote a T-cell-inflamed TME. Given the known requirement for EGFR signaling during 
pancreatic tumorigenesis (163–166) and erlotinib’s status as an FDA-approved medicine for PDA 
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(68), our results highlight the potential use of this drug as an immunotherapy-sensitizing agent for 





















An in vivo CRISPR screen identifies epigenetic regulators of tumor immunity in PDA  
We previously established a group of clonal congenic primary tumor cell lines from the 
KPCY mouse model of spontaneous PDA (87,155). Upon implantation into immunocompetent 
C57BL/6 mice, these clones recapitulate the heterogeneity of the immune TME seen in human 
PDA, with genomic and epigenetic differences, rather than tumor mutational burden, accounting 
for the observed differences in immune cell infiltration (155). To better understand the epigenetic 
differences distinguishing T-cell-inflamed and non-T-cell-inflamed samples, we used ATAC-seq 
(assay for transposase-accessible chromatin coupled with sequencing) to compare the two groups. 
This analysis revealed different chromatin accessibility patterns between T-cell-inflamed and non-
T-cell-inflamed samples, and that differences in the epigenetic landscape of cancer cells correlate 
with differences in the corresponding TME (Supplementary Figures S1A-B). This finding is 
consistent with recent studies describing functions of epigenetic regulators in modulating anti-tumor 
immunity in other types of cancer (18,167–170). 
T-cell-inflamed and non-T-cell-inflamed tumors derived from our panel of PDA tumor cell 
clones exhibit heterogenous responses to a combination immunotherapy regimen consisting of 
gemcitabine (G), abraxane (A), CD40 agonistic antibody (F), CTLA4 blocking antibody (C) and PD1 
blocking antibody (P), hereafter referred to as GAFCP (15,19,155). GAFCP therapy improves 
clinical outcomes in preclinical mouse models of PDA (171,172), and a similar regimen has shown 
promising results and is currently being tested in a Phase 2 clinical trial of patients with metastatic 
PDA (NCT03214250) (173). When challenged with GAFCP, PDA tumor cell clone 6419c5 – a non-
T-cell-inflamed tumor with abundant myeloid cells and a paucity of tumor-infiltrating T cells (155) – 
responded modestly to GAFCP therapy, with no tumor regressions (Supplementary Figure S1C). 
Nevertheless, RNA sequencing (RNA-seq) of tumor cells sorted from subcutaneously implanted 
tumors that were treated with either control or GAFCP therapy revealed significant transcriptional 
differences (Supplementary Figures S1D-E). Specifically, tumor cells that persisted following 
GAFCP treatment were enriched for gene signatures similar to those enriched by untreated T cell 
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low clones compared to T cell high clones (Supplementary Figure S1F). These results indicated 
that the transcriptional networks underlying T cell infiltration status mirror those that define 
sensitivity to immunotherapy. Thus, we concluded that this model would be a suitable platform for 
investigating other epigenetic and transcriptional regulators that shape the immune TME and 
influence response to immunotherapy in PDA.  
 To systematically interrogate tumor cell intrinsic epigenetic factors modulating anti-tumor 
immunity, we devised an in vivo focused CRISPR screen strategy (Figure 1A). First, we engineered 
the 6419c5 tumor cell clone to stably express Cas9 and then transduced it with a sgRNA library 
(174) consisting of 5100 sgRNAs targeting 850 epigenetic factors and RNA-binding factors, as well 
as 100 non-targeting control sgRNAs. We passaged the transduced cells in vitro for 12 days to 
allow for genome editing and then transplanted the cells into immunocompetent C57BL/6 mice. 
After 11 days, mice were treated with either vehicle or GAFCP therapy for an additional 12-14 days. 
Samples were collected at two timepoints prior to implantation (“T0” and “pre-injection) and from 
control- and GAFCP-treated tumors at the end of the experiment. Following sequencing, the 
representation of each sgRNA was measured for each sample and compared pairwise with all other 
samples.  
 To confirm the robustness of the screening platform and strategy, we first identified genes 
whose sgRNAs were depleted from tumor cells in both the Ctrl and GAFCP groups compared to 
the pre-injection sample, as such genes would likely be important for tumor growth and progression 
in vivo. As sgRNAs targeting DNA methyltransferase 1 (Dnmt1) were the most highly depleted 
(Supplementary Figures S2A-B), we knocked out Dnmt1 (Dnmt1-KO) in two PDA tumor cell clones, 
6419c5 and 6694c2 (Supplementary Figure S2C). This resulted in a decreased ability to form 
tumors (Supplementary Figure S2D), confirming the importance of Dnmt1 in tumor growth. 
Moreover, flow cytometry revealed increased infiltration of T cells and decreased infiltration of 
myeloid cells in Dnmt1-KO tumors (Supplementary Figures S2E-F). T cell depletion partially 
restored the Dnmt1-KO cells’ tumorigenic and growth capacities (Supplementary Figures S2G-H), 
consistent with recent findings in other cancers, which showed that DNMT1 promotes tumor growth 
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by suppressing anti-tumor immunity (175). Thus, our screening strategy can detect genes that 
control anti-tumor immunity to modulate tumor growth in vivo.  
 
Tumor cell intrinsic lysine demethylase 3A (KDM3A) suppresses anti-tumor immunity in PDA 
We next identified genes targeted by sgRNAs that are depleted from tumor cells in the 
GAFCP group compared to the Ctrl group. Filtering by p-value (< 0.025) and number of good 
sgRNAs (> 3) nominated 7 epigenetic regulators as potential suppressors of immunotherapy 
response (Figure 1B and Supplementary Figure S3A). To determine whether the hits in our screen 
regulate immune cell composition in the TME, we individually knocked out all seven genes in 
6419c5 (Supplementary Figure S3B). Given that the makeup of the immune TME, particularly T 
cells and myeloid cells, determines the responsiveness of PDA tumors to GAFCP treatment, we 
screened the tumors derived from the mutant clones for changes in immune infiltrates by flow 
cytometry. In 5 of the 7 mutants (Prdm8, Atf2, Kdm3a, Ep400, and Prdm5), we observed a 
significant increase in intratumoral T cells and a significant decrease in intratumoral myeloid cells 
(Supplementary Figure S3C), suggestive of a reprogramming of the immune landscape. We then 
deleted the top three hits from the screen (Prdm8, Atf2, Kdm3a) in a second PDA tumor cell clone 
(6694c2) and observed a similar change in immune infiltration in Kdm3a mutants but not in the 
other two genes (Supplementary Figures S3D-F). Moreover, KDM3A has recently been shown to 
promote PDA progression in animal models (176), and an analysis of TCGA data revealed KDM3A 
as the only gene among the 7 candidates whose elevated expression in PDA correlates with poor 
clinical outcome (Supplementary Figures S3G-H). Based on these observations, we focused our 
attention on the immune TME regulatory activities of KDM3A. 
Next, we performed a more detailed characterization of KDM3A’s impact on the tumor 
immune microenvironment. In subcutaneous tumors, Kdm3a loss was associated with an increase 
in tumor-infiltrating T cells and dendritic cells (DCs) and a concomitant decrease in myeloid cells 
compared to wildtype (WT) tumors (Figures 1C-D and Supplementary Figure S3I). This trend was 
confirmed in an orthotopic transplantation model (Figures 1E-G and Supplementary Figure S3J). 
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Accordingly, subcutaneously implanted Kdm3a-KO tumors acquired a marked sensitivity to GAFCP 
therapy compared to WT tumors, with most exhibiting a complete regression that led to a marked 
extension of survival (Figures 2A-C). These results demonstrate that KDM3A is an epigenetic 
suppressor of anti-tumor immunity and that loss of KDM3A reprograms the immune TME to a T-
cell-inflamed state, thereby conferring sensitivity to combination immunotherapy.  
 
Transcriptional and epigenetic profiling identifies KLF5 and SMAD4 transcription factors as 
potential mediators of KDM3A activity 
In previous work, transcriptional profiling of tumor cells identified several gene signatures 
that distinguish T cell high clones from T cell low tumors (155). For example, T cell low clone are 
enriched for TGFβ signaling and MYC signatures, while T cell high clones are enriched for 
interferon response signatures (155). When we performed RNA-seq and gene sent enrichment 
analysis (GSEA) (177) on sorted tumor cells from WT versus Kdm3a-KO tumors (Supplementary 
Figure S4A), we found that they enriched for similar molecular features that define T cell low and 
T cell high tumor cells, including TGFβ signaling and MYC signatures in WT tumor cells and 
interferon response signatures in Kdm3a-KO tumor cells (Supplementary Figures S4B-C). Kdm3a-
KO tumor cells also expressed higher levels of PD-L1 and MHC class I in vivo (Supplementary 
Figures S4D-E). When treated with interferon-gamma in culture, however, induction of MHC I and 
PD-L1 occurred to a similar degree in Kdm3a-KO cells and WT cells, suggesting that increased 
MHC class I expression by Kdm3a-KO cells is a consequence of the T-cell-inflamed TME 
(Supplementary Figure S4F). Collectively, these results suggest that KDM3A regulates gene 
networks similar to those which arise spontaneously during the formation of T cell inflamed and 
non-T cell inflamed tumors. 
To identify transcriptional regulators mediating KDM3A’s effects, we probed the epigenetic 
changes associated with KDM3A loss. Previous studies have identified KDM3A as a histone 
demethylase that co-localizes with and removes methylation from di-methylated histone H3 lysine 
residue 9 (H3K9me2) (178–183), a histone modification associated with transcriptional repression 
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(184–188). To unbiasedly examine global changes in histone modifications, we performed histone 
mass spectrometry analysis. No significant differences were observed between WT and Kdm3a-
KO cells (Supplementary Figure S4G), suggesting that KDM3A loss impacts H3K9me2 levels at a 
local rather than a global level.  
To characterize such locus-specific effects, we performed chromatin immunoprecipitation 
followed by next-generation sequencing (ChIP-seq) for both H3K9me2 and KDM3A. We observed 
that both signals were largely distributed in distal intergenic regions (Supplementary Figure S4H), 
as previously reported (189–192). Motif analysis revealed a strong signal for the consensus DNA 
binding sequence recognized by members of the KLF family of transcriptional regulators. KDM3A 
peaks that were lost in Kdm3a-KO cells enriched for the KLF motif (Figure 3A), which is highly 
conserved across multiple KLF family members (193). Accordingly, genomic regions enriching 
KDM3A ChIP-seq signals also included the KLF motif, consistent with a previous study in prostate 
cancer cells(189) (Figure 3B). Furthermore, we found that peaks associated with H3K9ac, a classic 
marker of active promoters (194,195), that were decreased in Kdm3a-KO cells also enriched for 
the KLF motif (Figure 3C). Moreover, we focused our attention on Klf5 as it was the mostly 
downregulated member of the KLF family in Kdm3a-KO cells (Figure 3D and Supplementary Figure 
S4I) and whose expression positively correlated with the expression of KDM3A in human PDA 
samples (Figure 3E). An analysis of TCGA data also showed that KLF5 expression in PDA 
correlates with poor clinical outcome (Supplementary Figure S4J). Further examination of the RNA-
seq data also identified SMAD4, which has recently been implicated in suppressing anti-tumor 
immunity in PDA and other types of cancers (15,196,197), as a possible mediator of KDM3A’s 
immune regulatory activity. Specifically, genes whose expression decreased upon KDM3A loss 
were enriched for both KLF and SMAD4 DNA binding motifs (Supplementary Figure S4K), as well 
as the SMAD4-activating TGFβ Hallmark gene set (Figure 3F). Interestingly, Kdm3a-KO cells 
expressed lower levels of factors that have previously been shown to promote a T cell low 
microenvironment in PDA (Figure 3D), including Epha2, Ptgs2, and Csf2 (15–17). Taken together, 
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our transcriptomic and epigenomic analyses nominated KLF5 and SMAD4 as transcriptional 
regulators that may coordinate the output of KDM3A’s epigenetic program. 
 
Loss of tumor cell intrinsic KLF5 or SMAD4 promotes a T-cell-inflamed TME 
To functionally examine the role of KLF5 and SMAD4 on anti-tumor immunity, we knocked 
out Klf5 and Smad4 – along with several other transcription factors downregulated with Kdm3a loss 
– in T cell low clone 6694c2 (Supplementary Figure S5A). These cells were implanted into 
immunocompetent mice, and immune infiltrates in the resultant tumors were examined by flow 
cytometry. Here, just as we saw with loss of KDM3A, we observed a significant increase of T cells 
and a concomitant decrease of myeloid cells with loss of KLF5 or SMAD4 (Figure 4A and 
Supplementary Figure S5B). Importantly, none of the other transcription factors representing 
potential KDM3A mediators yielded consistent changes in immune infiltration other than SMAD3, 
a binding factor of SMAD4 (Supplementary Figure S5C). The effect of KLF5 on immune infiltration 
was also confirmed using an orthotopic model and in a second T cell low clone (Figures 4B-D and 
Supplementary Figures S5D-F). These results demonstrate that KLF5 and SMAD4 act within tumor 
cells to promote intratumoral infiltration of myeloid cells and exclusion of intratumoral T cells.  
 Next, we compared the transcriptional profiles of tumor cells sorted from subcutaneously 
implanted Kdm3a-KO, Smad4-KO, and Klf5-KO tumors (Supplementary Figure S5G). GSEA 
analysis revealed that loss of Klf5 or Smad4 enriched for the gene signature defining Kdm3a-KO 
cells (Figure 4E). Furthermore, ablation of Klf5 resulted in transcriptional alterations that 
recapitulated those seen with loss of Smad4 (Figure 4F). Moreover, deletion of either KLF5 or 
SMAD4 resulted in a negative enrichment of the TGFβ signature, as was observed for KDM3A 
(Figure 4G). Collectively, these results suggest that KLF5, SMAD4, and KDM3A coordinately 
regulate transcription in tumor cells to suppress anti-tumor immunity. 
 




Since KDM3A, KLF5, and SMAD4 broadly regulate a shared transcriptional network, we 
sought to identify downstream pathways and gene targets on which all three converge. The 75 
genes that were consistently decreased following ablation of Kdm3a, Klf5, or Smad4 enriched most 
significantly for the KRAS signaling gene set (Figures 5A-C). Interestingly, genes encoding 
members of the epidermal growth factor (EGF) family of growth factors, as well as the EGF receptor 
(EGFR) itself, were among those showing the most consistent downregulation following ablation of 
these genes (Figure 5B and Supplementary Figure S6A).  Several additional findings led us to 
focus on EGFR as a potential mediator of the KDM3A-KLF5-SMAD4 axis: (i) TGFβ treatment, 
which activates SMAD4 transcriptional activity, induced the expression of Egfr (Supplementary 
Figure S6B); (ii) analysis of the Cancer Dependency Map Portal (DepMap) (198) revealed EGFR 
to exhibit the greatest co-dependency with KLF5 for survival across tumor lines as compared to 
any other gene (Figure 5D); and (iii) in PDA patient samples, EGFR expression correlated with 
KDM3A and KLF5 expression (Figure 5E) and worse clinical outcome (Supplementary Figure S6C). 
To determine whether EGFR has a role in anti-tumor immunity, we knocked out EGFR in 
two PDA tumor cell clones and assessed the immune infiltration of the resulting tumors from both 
subcutaneous and orthotopic tumor models. As observed previously with KDM3A, SMAD4, and 
KLF5, loss of EGFR rewired the immune TME from a non-T-cell-inflamed state to a T-cell-inflamed 
state (Figures 5F-G and Supplementary Figures S6D-F). Remarkably, transcriptomic analysis of 
Egfr-KO cells revealed dysregulation of the same genes and pathways that were perturbed in 
Kdm3a, Klf5, and Smad4-KO cells (Figures 5H-I), including downregulation of the TGFβ gene set 
and induction of interferon response gene sets. Importantly, among the 75 genes that were 
decreased by loss of Kdm3a, Klf5, and Smad4, 70 genes were also decreased following ablation 
of EGFR (Supplementary Figure 6G). In addition, the tumor cell intrinsic expression of two immune 
modulatory secreted factors (CSF2 and PTGS2) that we and others have previously shown to 
promote a non-T-cell-inflamed TME (15–17) in PDA was also decreased across all four mutants 
compared to wild type tumor cells (Figure 3A, Figure 5B, and Supplementary Figure S6G). Taken 
together, these results suggest that KDM3A, KLF5, SMAD4, and EGFR converge on a conserved 
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transcriptional program in cancer cells, which in turn influences the composition of the tumor 
immune microenvironment.   
 
EGFR inhibition creates a conducive environment for enhancing immunotherapy  
Clones lacking Klf5, Smad4, or Egfr gave rise to tumors with a reduction in myeloid cells 
and an increase in T cells. Hence, we sought to determine whether these tumors responded to 
GAFCP immunotherapy, as we had earlier shown for Kdm3a mutants (Figure 2). We found that 
tumors derived from Klf5-, Smad4-, or Egfr-KO tumor cells all became sensitized to GAFCP 
therapy, leading to tumor regression and improved animal survival, whereas parental cells showed 
minimal response (Figure 6A). Therefore, the changes in immune infiltrates caused by loss of KLF5, 
SMAD4 or EGFR are sufficient to sensitize tumors to the effects of combination immunotherapy.  
EGFR signaling has been shown to play a central role in PDA biology (68,163–
166,199,200). Erlotinib, a tyrosine kinase inhibitor (TKI) of EGFR, is approved for the treatment of 
PDA patients based on a small but significant clinical benefit (68). Importantly, these modest clinical 
effects were observed in the absence of any adjunctive immunotherapies. Given that deletion of 
the Egfr gene results in a T-cell-inflamed TME, we hypothesized that pharmacologic inhibition of 
EGFR might similarly shift the tumor immune landscape. Consistent with this hypothesis, we found 
that erlotinib treatment of subcutaneous or orthotopic 6694c2 tumors prompted a dramatic and 
dose-dependent increase in intratumoral T cells and decrease in intratumoral myeloid cells (Figures 
6B-C and Supplementary Figures S7A-B). A more modest trend was observed in tumors derived 
from clone 6419c5 (Supplementary Figures S7C-D), a difference that may be explained by the high 
abundance of gMDSCs in these tumors, a feature that has been associated with resistance to 
EGFR inhibitors (201). Therefore, pharmacologic inhibition of EGFR modulates the immune TME 
and may create a permissive environment for effective immunotherapy in non-T-cell-inflamed 






Tumor heterogeneity describes distinct features that include both tumor cell intrinsic and 
extrinsic properties (202). Functionally, heterogeneous immune TMEs lead to distinct responses to 
immunotherapy (149). Recent studies have highlighted the role of tumor cell intrinsic factors in 
modulating both the abundance and activation of T cells and the consequences for productive anti-
tumor immunity (152–154). A full understanding of these molecular regulators could inform novel 
therapeutic strategies to enhance the efficacy of existing immunotherapies. This principle is 
particularly relevant to PDA, which is refractory to most existing treatment options, including ICB-
based immunotherapy(203). CRISPR loss-of-function genetic screening has been used to discover 
novel molecular regulators of anti-tumor immunity. Specifically, two recent studies utilized in vivo 
CRISPR screen strategies to unbiasedly identify potential therapeutic targets in melanoma and 
lung cancer (170,204). The current study is, to our knowledge, the first in vivo screen to identify 
tumor cell-intrinsic factors that can mediate anti-tumor immunity in pancreatic cancer.  
We and others have shown that genomic mutations are unlikely to explain immune TME 
heterogeneity (15–17,19,155,162,205,206). Based on our observation that T-cell-inflamed and 
non-T-cell-inflamed tumor cells possess different epigenetic landscapes, we designed a screen to 
identify epigenetic factors important for immunotherapy responsiveness in vivo. Using this 
approach, together with transcriptional and epigenetic profiling and functional validation studies, 
we conclude that KDM3A, KLF5, and SMAD4 transcriptionally converge on EGFR to maintain a T 
cell low TME and drive resistance to immunotherapies.  
Our findings are in line with recent preclinical studies showing the ability of small molecule 
inhibitors of EGFR to enhance the efficacy of immunotherapy. For example, one recent study 
demonstrated that EGFR inhibition increased the sensitivity of EGFR-mutated non-small cell lung 
cancer to ICB-based immunotherapy (207). Importantly, the EGFR inhibitor erlotinib is FDA 
approved for treating pancreatic cancer in combination with gemcitabine (68). EGFR signaling has 
been shown to play an important role in pancreatic cancer progression (68,163–166), but the 
clinical benefit from erlotinib treatment in PDA patients has been limited (68,165). The current study 
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provides a rationale for further examining whether the combination of EGFR inhibition with 
immunotherapies will elicit a more potent response, not just in pancreatic cancer but also other 
KRAS-driven cancers such as lung cancer. In this respect, it is noteworthy that the combination 
therapy used in this study (GAFCP) is similar to one being evaluated in a phase II clinical trial for 
PDA (NCT03214250) and for which promising phase I data have been reported (173). As 
resistance to EGFR-targeting tyrosine kinase inhibitors is frequently observed (208–210), a deeper 
understanding of the molecular mechanisms underlying EGFR-mediated control of anti-tumor 
immunity is needed. 
Accumulating evidence shows that different tumors exploit distinct cellular and molecular 
mechanisms to establish non-T-cell-inflamed TMEs (155,211). Consequently, further subtyping of 
non-T-cell-inflamed tumors and identification of subtype-specific immunosuppressive modules will 
be important for precision medicine and improved efficacy of immunotherapy. This might be 
particularly relevant to our observation that different T cell low PDA tumors vary in their sensitivity 
to erlotinib treatment. Since it has been previously shown that an increased abundance of gMDSCs 
is associated with therapy resistance, non-T-cell-inflamed tumors having an overabundance of this 
cell type might derive particular benefit from treatment with anti-gMDSCs agents (212). 
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Materials and Methods 
Animals  
All mouse experiment procedures used in this study were performed following the National 
Institutes of Health guidelines. All mouse procedure protocols utilized in this study were in accordance 
with, and with the approval of, the Institutional Animal Care and Use committee (IACUC) of the 
University of Pennsylvania. All wild-type C57BL/6 were purchased from The Jackson Laboratory and/or 
bred and maintained at the University of Pennsylvania.  
 
PDA tumor cell clones and cell lines 
Mouse pancreatic tumor cell clones were generated in our lab recently (155), and were 
examined by the Research Animal Diagnostic Laboratory (RADIL) at the University of Missouri, using 
the Infectious Microbe PCR Amplification Test (IMPACT) II. PDA tumor cells were cultured in standard 
cell culture medium including DMEM (high glucose without sodium pyruvate, Corning, 10-017-CV) with 
10% heat-inactivated FBS (Genesee Scientific 25-514) and Glutamax (Thermo 35050061). These 
tumor cell clones were used for less than 20 passages. YFP labeling of these tumor cell clones were 
derived from their genetic background (these tumor cell clones were derived from the KPCY mice as 
described in our previous report(87)). We used 293T cells (Clontech, 632180) for lentivirus packaging. 
 
Implantation of tumor cells 
Pancreatic tumor cells were dissociated into single cell suspension with 0.25% trypsin for 3 
minutes at room temperature (Gibco), washed with serum-free Dulbecco's Modified Eagle's medium 
(DMEM) twice, and counted in preparation for subcutaneous or orthotopic implantations. 2.0x105 PDA 
tumor cells were implanted subcutaneously and 5.0x104 PDA tumor cells were implanted orthotopically 
into the pancreas of 6-8-week old female C57BL/6 mice as previously described. Tumors were 
harvested 17-24 days following implantation for flow analysis, fixation, and other described 
experiments. Endpoint criteria included tumor volume exceeding 500 mm3, severe cachexia, or 




Subcutaneous tumor growth and regression assessments  
For tumor growth assessment, tumors were measured every 3-4 days. Tumor length and width 
were examined with calipers, and tumor volumes were then calculated as length*width2/2. Tumor 
volumes of 500 mm3 were used as an endpoint for overall survival analysis following our mouse 
protocols. Tumor progression and/or regressions and were calculated using the initial tumor size at the 
start of treatment to tumor size at the end point of analysis for calculation.  
 
Treatments and T-cell depletions in mice 
For therapy treatment, Gemcitabine (Hospira) and Nab-paclitaxel (Abraxane, Celgene) were 
both purchased from the Hospital of the University of Pennsylvania Pharmacy. Gemcitabine (G) was 
procured as pharmaceutical grade suspension at 38 mg/mL, and then diluted to 12 mg/mL in PBS and 
administered at 120 mg/kg via intraperitoneal (i.p.) injection. Abraxane (A) was purchased as a 
pharmaceutical grade powder resuspended at 12 mg/mL in PBS for i.p. injection at dose of 120 mg/kg. 
Vehicle control mice received the equivalent to nab-paclitaxel dose of human albumin (huAlb; Sigma). 
For anti-CD40 agonist treatment, mice were injected i.p. with 100 μg of either agonistic CD40 rat anti-
mouse IgG2a (clone FGK45, endotoxin-free) or the isotype control IgG2a (clone 2A3, BioXcell) 48hrs 
after chemotherapy. For checkpoint blockade treatment, mice were injected i.p. with 200 μg of anti–
PD-1 (clone RMP 1-14, BioXcell) and 200 μg anti–CTLA-4 (clone 9H10, BioXcell), beginning from 
described therapy start timepoint, with 6 and 3 doses, respectively. Control mice received the isotype 
control IgG2a (clone 2A3, BioXcell) on treatment days. Therapy was started when tumor was 3-5 mm 
size. CD4+ and CD8+ T cells were depleted using i.p. injections of 200 mg anti-CD4 (clone GK1.5, 
BioXcell) and anti-CD8 (clone 2.43, BioXcell), three days prior tumor implantation, and every three days 
for the duration of the experiment. Control groups received IgG2b isotype control (BioXcell). For 
erlotinib treatment, we prepared 500mg erlotinib (HY-50896) in DMSO and then diluted the drug in corn 
oil (5ml DMSO + 45mL corn oil) for a final concentration of 10 mg/mL. We delivered 100 mL and 200 




CRISPR-Cas9 screen analysis 
Cas9 protein was introduced to the 6419c5 PDA tumor cell clone by transduction of the 
lentiCas9-Blast plasmid (Addgene plasmid #52962) and selected with 10 µg/mL Blasticidin. Tumor cells 
were transduced with sgRNA lentivirus library at MOI of 0.2. 1000x coverage of the sgRNA library in 
tumor cells were maintained during in vitro cell culture. Enough tumor cells were implanted into mice to 
maintain 500x coverage of the sgRNA library. Tumor cells were collected for library preparation to 
maintain at least 500x coverage of the sgRNA library in each sample. Genomic DNA from collected 
tumor cells was harvested using the QIAamp DNA mini kit (Qiagen), and libraries were prepared 
following previously described protocols (130). Briefly, DNA containing sgRNAs were amplified over 25 
cycles with Herculase II fusion DNA polymerase (Agilent) following manufacturer provided protocol with 
PCR.1 forward and reverse primer. 3 µg of genomic DNA were used for each PCR reaction, and several 
PCR reactions were run in parallel for each collected sample for maintaining library coverage. Product 
of PCR.1 reaction was pooled for each sample, and 5 µl of each pooled PCR.1 sample was used as a 
template for PCR.2. For PCR.2, template was amplified over 7 cycles with PCR.2 forward and reverse 
primers, and the resulting product were purified with the QIAquick PCR purification kit (Qiagen) followed 
by gel extracted with the QIAquick gel extraction kit (Qiagen). The barcoded libraries were pooled at 
an equal molar ratio and sequenced on a NextSeq500/550 (Illumina, 75 cycles High Output kit v2.0) to 
generate 75 bp single end reads. MAGeCK software was used for screen analysis (129). Briefly, the 
sequencing data were de-barcoded and merged, and the 20 bp sgRNA sequence was aligned to the 
reference sgRNA library without allowing for any mismatches. The read counts were calculated for each 
sgRNA using the method normalizing to the non-targeting sgRNAs. Differential analysis of sgRNA and 
targeted genes was also done following the MAGeCK instructions with standard parameters. 
 
RNA-seq 
RNA samples were extracted from sorted YFP+ tumor cells from subcutaneous tumors, using 
the Qiagen RNeasy Micro Kit following manufacturer’s instructions. RNA was sent out to a commercial 
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company, Novogene (California, USA), for library preparation and high-throughput sequencing using 
Illumina sequencers to generated paired-end results. Raw counts of gene transcripts were obtained 
using alignment-independent tool, Salmon (https://combine-lab.github.io/salmon/), using standard 
settings. The raw count matrix was subsequently imported into R-studio (R version 3.3.3) and used as 
input for DESeq2 following the vignette of the package for normalization and differential gene 
expression analysis. Salmon was used to normalize and quantitate gene expression in transcripts-per-
million (tpm) through quasi-alignment. Differentially expressed genes were used as input for GSEA and 
other functional analysis. Differentially expressed genes were also used as input for online EnrichR 
analysis following provided instructions (213,214). Detailed Scripts and parameters used for each steps 
of analysis could be provided by reasonable request to the authors. 
 
ATAC-seq 
For library construction, 50,000 tumor cells sorted from subcutaneously implanted tumors were 
used as input as previously described (155). The libraries were prepared as previously described with 
minor modifications (135). Briefly, nuclei were isolated from sorted cells using a solution of 10 mM Tris-
HC pH 7.4, 10 mM NaCl, 3 mM MgCl2, and 0.1% IGEPAL CA-630. Immediately following nuclei 
isolation, the transposition reaction was conducted using Tn5 transposase and TD buffer (Illumina) for 
45 min. at 37 degree. Transposed DNA fragments were purified using a Qiagen MinElute Kit, barcoded 
with primers based on Illumina TruSeq indices, and PCR amplified for 12 cycles using NEBNext High 
Fidelity 2x PCR master mix (New England Biolabs). Libraries were purified by extraction from a 6% 
TBE gel, followed by column purification with the Qiagen PCR Cleanup kit. Sequencing was performed 
using a HiSeq2500 (Illumina) on rapid run mode to generate 50 bp paired end reads.  For analysis, 
after adapter trimming with cutadapt, reads were aligned to the mouse reference genome (mm10) by 
Bowtie2. MACS2 was applied to identify accessible chromatin (215). Peaks were subsequently merged 
using BEDTools and ATAC-seq read counts were calculated in the merged peaks for every sample 
(137). The resulting count table was used to identify differentially accessible loci with edgeR, which 
were then used for functional analysis by GREAT analysis (version 3.0.0) (138,216,217). Detailed 
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For ChIP, about 1.5 x 107 cells were cultured on 15 cm plates with normal culture medium. 
Medium was changed to DMEM without serum first and then cells were crosslinked with 1.1% 
formaldehyde for 10 min at room temperature. Then samples were quenched with 125 mM glycine for 
5 min at room temperature on plate. Cells were then washed with cold PBS three times and then lysed 
with 1 mL nuclei isolation buffer for 15 min on ice (20mM PIPES, 85mM KCl, and 0.5% NP-40). Nuclei 
were spun down at 300 g for 5 min at 4 degree and resuspended in 500 uL ChIP lysis buffer with 
proteinase inhibitor (1% SDS, 10 mM EDTA pH 8, 50 mM Tris-HCl pH 8.0). Samples were then 
sonicated with a Diagenode Bioruptor at high intensity setting for 15 X 5 min cycles of 30 sec on/off, to 
yield about 300bp fragments. After centrifugation at 4 degree with 13,500 rpm for 10 min, soluble 
chromatin was then diluted using ChIP dilution buffer (0.01% SDS, 1.2 mM EDTA pH 8, 16.7 mM Tris-
HCl pH 8, 167 mM NaCl, and 1.1% Triton X 100), and pre-cleared with magnetic Protein G Dynabeads 
(Invitrogen, 10004D). Immunoprecipitation with anti-H3K9me2 (Abcam, ab32521), anti-H3K9ac 
(Abcam, ab4441), anti-KDM3A (Novus Biologicals, NB100-77282) was performed overnight at 4 
degree with rotation, with 10% sample kept as input DNA. Products were recovered with magnetic 
Protein G Dynabeads and washed sequentially using ChIP Low Salt Buffer (0.1% SDS, 2.0 mM EDTA 
pH 8.0, 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 1.0% Triton X 100), ChIP High Salt Buffer (0.1% SDS, 
2.0 mM EDTA pH 8.0, 20 mM Tris-HCl pH 8.0, 500 mM NaCl, 1.0% Triton X 100), Lithium Chloride 
Buffer (1 mM EDTA pH 8.0, 10 mM Tris-HCl pH 8.0, 250 mM LiCl, 1% NP-40, 1% sodium 
deoxycholate), and TE buffer (1 mM EDTA pH 8.0, 10 mM Tris-HCl pH 8.0) 10 min each buffer at room 
temperature. Samples were eluted twice using ChIP Elution Buffer (2% SDS, 100 mM NaHCO3) at 
room temperature for 15 min each elution with rotation. Eluted sample DNA was incubated with RNase 
A (0.2 mg/mL) overnight at 65°C, then incubated with Proteinase K (0.2 mg/mL) for 2 hours at 45°C. 
DNA samples were purified using QIAquick PCR Purification Kit (Qiagen) and used for preparation of 
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ChIP-seq libraries. Libraries were prepared following the NEBNext Ultra II DNA Library Prep Kit (New 
England Biolabs) protocol, using NEBNext Multiplex Oligos Index Primers Sets. Libraries were pooled 
and sequenced on the NextSeq500/550 (Illumina, 75 cycles High Output kit v2.0) to generate 75 bp 
single end reads. Sequencing reads were aligned to the mouse (mm10) using Bowtie2 with default 
settings (136). Resulted sam files were processed and marked with duplicates using SAMtools (140). 
Peaks calling was performed using MACS2 (215) with default settings. Peaks were subsequently 
merged using BEDTools and read counts were calculated in the merged peaks for every sample (137). 
The resulting count table was then used to find differentially genomic regions with edgeR (216,217). 
Differential genomic regions were then transformed to bed files and used for genomic region annotation 
using the ChIP-seeker analysis tool (218) as well as the motif analysis using the MEME suite (219). 
The DREME analysis and the Tomtom analysis were used in the MEME suite for motif discovery and 
motif comparison (220,221). The HOCOMOCO core collection of motifs (version 11) were used for the 
motif enrichment analysis. Detailed Scripts and parameters used for each steps of analysis could be 
provided by reasonable request to the authors. 
 
Cancer Dependency Map Portal data analysis 
The depmap portal (https://depmap.org/portal/) and the CRISPR (Avana) Public 19Q3 dataset 
were used for this analysis. No samples were excluded from the dataset in this analysis. Following the 
depmap instruction, the dependency scores of genes were downloaded and then plotted as dot plots. 
Pearson correlation was calculated for all the plots using Prism. 
 
Lentiviral transduction of tumor cells for CRISPR-mediated ablation  
The CRISPR vector, lentiCRISPR v2, was a gift from Feng Zhang (Addgene plasmid # 52961). 
The vector and pVSVg and psPAX2 lentiviral packaging plasmids (Addgene) were co-transfected into 
293T cells (Clontech, 632180) using PEI reagent (Polysciences, 23966-2). Lentiviral particles were 
collected 48 hours after transfection and filtered for usage. Tumor cells transduced either with Cas9-
Puro (control, ctrl) or Cas9-guide-Puro (knockout, KO) (ctrl is from Addgene, #52961, and KOs were 
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cloned following the instruction from Addgene) were selected with 8 μg/mL puromycin (Invitrogen, 
A1113803). Single-cell clones were picked from bulk knockout cell line using single-cell sorting using 
BD Jazz FACS sorting machine in to 96-well plates. Knockout efficiencies were assessed by gene-
specific qPCR analysis of target gene. CRISPR sgRNA sequences used were:  
Gene Forward Reverse 
Dnmt1 CACCGTGAAACTTCACCTAGTTCCG AAACCAAATAGATCCCCAAGATCCC 
Atf2 CACCGTGGACGAACGATAGCTGATG AAACCGTTCGTCCAGCATCATTACC 
Brd1 CACCGTAATTGAGCTGCTGCGCAAG AAACGAGCGTAGCAGCACAGTTAGC 
Cbx7 CACCGGGAAGAGAGGTCCGAAACCC AAACCCAGACGTTGTGCAGACCCCC 
Ep400 CACCGTCGGAACATGTAGGGCCGGC AAACCAGAAGCCGACCCCTTTAAGC 
Prdm5 CACCGGCTCGATTCACACTGTGGAC AAACGAGTTCAAATGCGAGAACTGC 
Prdm8 CACCGGCTCTTCCGCTCGTCCGATG AAACTGTTCTACCGCTCTCTCCGCC 
Kdm3a CACCGTACAGGATGTTAACAGTCTT AAACAACTCTTCAAGTCAACTGTGC 
Tead2 CACCGGAAGACGAGAACGCGAAAGC AAACTTCGAGCCAAAACCTGAATAC 
Mycn CACCGCGAGTACGTGCACGCCCTAC AAACGCCGACTCTCGCTTGTTCACC 
Prdm16 CACCGCTACGAGAGTCCTCCATACC AAACCCCGATTTCCATCTTCCGCTC 
Trim28 CACCGGGACCTGCTAAGACTCGAGA AAACATAATTCTCCACGATGTCTTC 
Klf5 CACCGCGCGTGTTTCAGATCGTCTC AAACTGCGAACCCGGCCCGCGACGC 
Smad3 CACCGGCTCCATGGCCCGTAATTCA AAACACCTACCTGGAATATTGCTCC 
Smad4 CACCGGCCAAGTAATCGCGCATCAA AAACTCCGTTGATGCGCGATTACTC 
Egfr CACCGCGGTCAGAGATGCGACCCTC AAACACTGCCCATGCGGAACTTACC 
 
Quantitative PCR (qPCR) 
RNA was prepared from cultured PDA tumor cells using the RNeasy Mini Kit or RNeasy Micro 
Kit (Qiagen). cDNA was generated using High-capacity cDNA Reverse Transcription Kit from 1 ug RNA 
in 20 ul reaction volume and diluted 1:10 for qPCR analysis (Life Technologies). qPCR analysis was 
performed using 2 ul diluted cDNA with biological and technical replicates using SsoAdvanced SYBR 
reagent (Bio-Rad) and Bio-Rad qPCR platform, and results were normalized to the expression of Tbp 
using the Bio-Rad software. Primer sequences utilized for qPCR were:  
Gene Forward Reverse 
Dnmt1 AAGAATGGTGTTGTCTACCGAC CATCCAGGTTGCTCCCCTTG 
Atf2 CCGTTGCTATTCCTGCATCAA TTGCTTCTGACTGGACTGGTT 
Brd1 AACACTGACCTACGCACAAGC GCCTCTCGCTGTTCTCCTTATT 
Cbx7 TGCGGAAGGGCAAAGTTGAAT ACAAGGCGAGGGTCCAAGA 
Ep400 CGGTTCTCAGGATAAACTGGC CACCTCCGCTCTTGAGCAA 
Prdm5 GAGAAGCGAATGCCTGAAGAC CTCCCACGTACCTCCCACA 
Prdm8 ATGGAGGATTCAGGCATCCAG GGACCGAATATGGCGTTCTCT 
Kdm3a GTGACACAACCATTTTCAACCTG CACCCTGTTGGCAGTTCTTC 
Tead2 GAAGACGAGAACGCGAAAGC GATGAGCTGTGCCGAAGACA 
Mycn ACCATGCCGGGGATGATCT AGCATCTCCGTAGCCCAATTC 
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Prdm16 CCCCACATTCCGCTGTGAT CTCGCAATCCTTGCACTCA 
Trim28 CGGCGCTATGGTGGATTGT GGTTAGCATCCTGGGAATCAGAA 
Klf5 CCGGAGACGATCTGAAACACG GTTGATGCTGTAAGGTATGCCT 
Smad3 CACGCAGAACGTGAACACC GGCAGTAGATAACGTGAGGGA 
Smad4 ACACCAACAAGTAACGATGCC GCAAAGGTTTCACTTTCCCCA 
Egfr GCCATCTGGGCCAAAGATACC GTCTTCGCATGAATAGGCCAAT 
Tbp AGAACAATCCAGACTAGCAGCA GGGAACTTCACATCACAGCTC 
 
Flow cytometry  
Subcutaneous or orthotopic tumors were chopped into small pieces and digested in 
collagenase (1 mg/mL in DMEM; Sigma-Aldrich) at 37 degree for 45 minutes and filtered through a 70-
μM cell strainer to generate single cell suspensions. Single cell suspensions were then stained with 
fluorescence labelled antibodies on ice for 40 minutes and washed twice with cold PBS with 5% FBS 
for flow cytometric analysis. Cells were then analyzed by flow cytometry using BD FACS (BD 
Biosciences) and FlowJo software (Treestar).  
Gating Strategies for immune cells:  
myeloid cells - Live CD45+CD11b+; granulocytic (g)MDSCs/neutrophils - Live CD45+CD11b+Gr1+; 
macrophages - Live CD45+F4/80+CD11b+; CD11c+ dendritic cells - Live CD45+F4/80– CD11c+; 
CD103+ dendritic cells - Live CD45+CD11b–F4/80–CD11c+ CD103+; T cells - Live CD45+CD11b–
F4/80–NKp46–CD3+; CD4+ T cells - Live CD45+CD11b–F4/80–NKp46–CD3+CD4+; CD8+ T cells - 
Live CD45+CD11b–F4/80–NKp46–CD3+CD8+.  
Antibodies used for flow analysis:  
CD279 (PD-1) FITC (29F.1A12) Biolegend 135214, CD335 (NKp46) PE (29A1.4) Biolegend 137604, 
CD103 PE/Dazzle 594 (2E7) Biolegend 121430, CD3e PE/Cy5 (145-2C11) Biolegend 100310, CD45 
AF700 (30-F11) Biolegend 103128, CD8a PE/Cy7 (53-6.7) Biolegend 100722, Ly-6G V450 (1A8) BD 
560603, H-2Kb/H-2Db (MHCI) AF647 (28-8-6) Biolegend 114612, F4/80 APC/Cy7 (BM8) Biolegend 
123118, CD11b PerCP-Cy5.5 (M1/70) BD 550993, CD11c BV605 (N418) Biolegend 117334, Ly-6C 





PDA tumor cells were plated into 6-well plates and 24 hours later were treated with either citric 
acid (control) or 10 ng/mL TGFβ (CST) over 3 days for RNA collection for RNA-seq analysis. 
 
In vitro treatment with IFNγ for MHC I expression analysis 
Kdm3a-WT and Kdm3a -KO PDA tumor cells were treated with 100ng/mL of IFNγ (Peprotech) 
in cell culture medium for 24 hours. Tumor cells were then trypsinized from culture plates and re-
suspended in PBS with 5% FBS for staining of antibodies. Tumor cells were then stained with MHCI 
(Biolegend 114612) antibody on ice for 40 minutes and washed twice with cold PBS with 5% FBS for 
flow cytometric analysis using BD FACS LSR machine (BD Biosciences) and FlowJo software 
(Treestar). 
 
Immunofluorescent and immunohistochemistry staining  
For CD3 and Gr1 staining, collected implanted tumor tissues were fixed in Zn-formalin for 24 
hours and embedded in paraffin. Sections were deparaffinized, rehydrated, and prepared by antigen 
retrieval for 6 minutes each, and then blocked in 5% donkey serum (Sigma, D9663) for 1 hour at room 
temperature, incubated with primary antibodies overnight at 4°C, washed with 0.1% PBST (PBS with 
Tween-20), incubated with secondary antibodies for 1 hour at room temperature, and then washed and 
mounted. Slides were visualized and imaged using an Olympus IX71 inverted multicolor fluorescent 
microscope and a DP71 camera. For CD3 and Gr1 staining quantification, stained cells were counted 
for CD3+ T cells manually in 5-8 fields per sample.  
Primary antibodies: CD3 (Abcam ab5690, 1:100 dilution) and Gr-1 (eBioscience 14-5931-85, 1:50 
dilution), YFP (Abcam, ab6673). Secondary antibodies were purchased from Invitrogen (A-11055, A-
21207, A-21209) and were used as 1:250 dilution for all staining.  
 
Immunoblotting 
For whole cell lysates, cells were washed with PBS and lysed in RIPA lysis buffer. Extracted 
proteins were separated by SDS-PAGE, transferred to PVDF membrane, blocked in 5% non-fat milk in 
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PBS with 0.1% Tween-20, probed with primary antibodies, and detected with horseradish peroxidase-
conjugated secondary antibodies (Jackson Immunoresearch). Primary antibodies used include: 
KDM3A (Novus Biologicals, NB100-77282), alpha-TUBULIN (CST, 3873S). 
 
Histone extraction, derivatization, mass spectrometry, and PTM mark quantification 
For extraction, histones were acid extracted according to standard protocols. Briefly, nuclei 
were isolated from cells lysed with a hypotonic lysis buffer. Histones were extracted from the nuclei 
with 0.2N H2SO4, precipitated in 33% trichloroacetic acid (TCA), washed with acetone, and 
resuspended in diH2O. For derivatization, histones were derivatized according to standard 
protocol(143). Briefly, 5-10ug of acid-extracted histones were resuspended in 100mM ammonium 
bicarbonate (pH 8.0) and mixed with freshly prepared propionic anhydride with acetonitrile for 15 min. 
at 37 °C. Histones were then digested with trypsin (enzyme: sample ratio 1:20) overnight at 37 °C. The 
peptides were then desalted and stored dried. They were resuspended in 0.1% formic acid just before 
mass spectrometry. For direct injection–MS, samples were placed in a TriVersa NanoMate (Advion) 
and acquired either manually or by using a sequence coordinated with MS acquisition by a contact 
closure. The NanoMate was set up with a spray voltage of 1.7 kV and a gas pressure of 0.5 psi. 
Samples were acquired in the Orbitrap Fusion Tribrid (Thermo Scientific). All scans were acquired in 
the orbitrap, at 240,000 resolution for the full MS and at 120,000 resolution for MS/MS. The AGC target 
for the tSIM-MSX scans was set to 10E6. The full description of the DI-MS acquisition method has been 
previously described (144). For histone peptide quantification, raw files were searched with a modified 
version of the software EpiProfile 2.064 (145). Histone peptides are collected in MS scans, and isobaric 
peptides are collected in targeted pre-set MS/MS scans. The software reads the intensities from MS 
scans to calculate the percentage of all peptides with the same amino acid sequence. The unique 
fragment ions in the MS/MS scans are extracted to discriminate isobaric peptide intensities from the 





Software and Statistical analysis  
PRISM software and R were used for data processing, statistical analysis, and result 
visualization (http://www.graphpad.com). The R language and environment for graphics (https://www.r-
project.org) was used in this study for the bioinformatics analysis of CRISPR screen, RNA-seq, and 
ChIP-seq data. The R packages used for all analysis described in this manuscript were from the 
Bioconductor and CRAN. Statistical comparisons between two groups were performed using Student’s 
unpaired t test. For comparisons between multiple groups, one-way ANOVA with Tukey’s HSD post-
test was used. For survival comparison between two groups, log-rank p-values of Kaplan-Meier curves 
were determined in GraphPad Prism 8 (GraphPad). On graphs, bars represent either range or standard 
error of mean (SEM), as indicated in legends. For all figures, p<0.05 was considered statistically 





Figure 1: A genetic screen identifies KDM3A as a tumor cell intrinsic epigenetic regulator 
suppressing anti-tumor immunity in pancreatic cancer. (A) Diagram showing the strategy of 
an in vivo CRISPR-based genetic screen. (B) Volcano plot showing the comparison between 
GAFCP and Ctrl groups. Each dot represents a gene whose sgRNAs were enriched in Ctrl (blue) 
or GAFCP (red) groups, with p-value < 0.05. Several top candidate epigenetic regulators, with p-
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value < 0.025 and good.sgRNAs >3 are highlighted. (C) Top: representative immunofluorescent 
staining images of CD3+ T cells and Gr1+ myeloid cells in Kdm3a-WT or Kdm3a-KO tumors stained 
for CD3 or Gr1 (red) and YFP (green). Bottom: quantification of CD3+ T cells and Gr1+ myeloid 
cells comparing Kdm3a-WT and Kdm3a-KO tumors (counts taken from n=5-8 images/group; data 
combined from two independent 6419c5 knockout clones). (D) Flow cytometric analysis of tumor 
infiltrating immune cells in subcutaneously implanted Kdm3a-WT and Kdm3a-KO 6419c5 and 
6694c2 tumors (n=9-13/group). (E) Flow cytometric analysis of tumor infiltrating immune cells in 
orthotopically implanted Kdm3a-WT and Kdm3a-KO 6419c5 and 6694c2 tumors (n=5-10/group). 
(F-G) Representative flow plots showing the abundance of myeloid cells (F) and T cells (G) within 
total CD45+ leukocytes in Kdm3a-WT (blue) or Kdm3a-KO (red) tumors. In (C), statistical 
differences were calculated using unpaired Student’s t-test. In (D-E), statistical differences were 
calculated using Multiple T test. Throughout the study, p<0.05 was considered statistically 

















Figure 2: Genetic ablation of tumor cell intrinsic KDM3A promotes a T-cell-inflamed TME in 
PDA. (A) Growth curves of Kdm3a-WT or Kdm3a-KO tumors from two non-T-cell-inflamed lines 
(6419c5 and 6694c2) with or without GAFCP treatment. (B) Overall survival curves of animals with 
Kdm3a-WT or Kdm3a-KO tumors with or without GAFCP treatment. (C) Waterfall plots showing 
change in tumor size of Kdm3a-WT or Kdm3a-KO tumors relative to the start of treatment measured 
with or without GAFCP treatment. In (A-C), tumor cells were subcutaneously implanted into 
C57BL/6 mice (2 knockout tumor cell clones for each parental PDA tumor cell clone were used, 
n=5-16/group). In (A), statistical differences were calculated using unpaired Student’s t-test. In (B), 



















Figure 3: Transcriptional and epigenetic profiling identifies KLF5 and SMAD4 as potential 
transcriptional regulators downstream KDM3A. (A-C) Graphs showing the top enriched motifs 
of transcriptional regulators in genomic regions with lost H3K9me2, gained H3K9ac, and gained 
KDM3A ChIP-seq signals in Kdm3a-WT tumor cells compared to Kdm3a-KO tumor cells (q-value 
< 0.01 following the DREME and Tomtom based motif analysis, using ChIP-seq analysis of both 
6419c5 and 6694c2 tumor cell clones). Two knockout clones from each parental tumor cell clone 
were pooled together for ChIP-seq analysis (n=2/group, 8 samples in total). (D) Volcano plot 
illustrating the differential gene expression between sorted YFP+ tumor cells from Kdm3a-WT or 
Kdm3a-KO tumors (6419c5 and 6694c2 tumor cell clones, 2 knockout clones of each parental 
tumor cell clone were used, n=3/group and 18 samples in total). Each dot represents a gene 
(Kdm3a-WT (blue) or Kdm3a-KO (red), with p.adj-value < 0.05). Several factors known to drive a 
non-T-cell-inflamed TME in PDA are highlighted. (E) Dot plot showing the expression of KDM3A 








Figure 4: Genetic ablation of tumor cell intrinsic KLF5 and SMAD proteins promotes a T-
cell-inflamed TME in PDA. (A) Flow cytometric analysis of immune cells in subcutaneously 
implanted WT, Klf5-KO or Smad4-KO 6694c2 tumors (n=10/group, two knockout clones/gene). (B) 
Flow cytometric analysis of immune cells in orthotopically implanted WT and Klf5-KO 6694c2 
tumors (n=5-10/group, two knockout clones/gene). (C) Flow cytometric analysis of immune cells in 
subcutaneously implanted WT and Klf5-KO 6419c5 tumors (n=4-6/group, two knockout 
clones/gene). (D) Representative flow plots showing the abundance of myeloid cells and T cells 
within total CD45+ leukocytes in Klf5-WT (blue) or Klf5-KO 6694c2 (red) tumors. (E) Leading-edge 
plots from the GSEA analysis highlighting the enrichment of KLF5 and SMAD4 gene signatures 
based on the RNA-seq analysis of Kdm3a-WT or Kdm3a-KO tumor cells (gene signatures were 
generated based on p.adj-value < 0.01 and fold change > 2). (F) Leading-edge plots from the GSEA 
analysis highlighting the enrichment of the SMAD4 gene signature based on the RNA-seq analysis 
of Klf5-WT or Klf5-KO tumor cells (gene signatures were generated based on p.adj-value < 0.01 
and fold change > 2). (G) Leading-edge plots from the GSEA analysis highlighting the enrichment 
of the Hallmark_TGF_beta_signaling geneset. In (A), statistical differences were calculated using 
one-way ANOVA with multiple comparisons. In (B-C), statistical differences were calculated using 













Figure 5: Molecular profiling identifies EGFR as a tumor cell intrinsic factor regulating the 
immune TME and sensitivity to combination immunotherapy in PDA. (A) Venn diagram 
showing the overlap of differentially expressed genes in Klf5-KO, Kdm3a-KO, and Smad4-KO 
tumor cells compared to WT. (B) Heatmap showing expression of the 75 overlapped genes in (A). 
(C) Graph showing the top enriched hallmark genesets based on the GSEA of overlapped genes 
identified in (A). (D) Dot plot showing the dependency scores for EGFR and KLF5 across all 
tumor cell lines in the Project Achilles/Cancer Dependency Map Portal (DepMap). (E) Dot plot 
showing the expression of EGFR, KDM3A and KLF5 in the TCGA PAAD dataset. (F) Flow 
cytometric analysis of immune cells in subcutaneously implanted WT and Egfr-KO 6419c5 and 
6694c2 tumors (n=7-16/group, 2 knockout clones from each parental tumor cell clone). (G) Flow 
cytometric analysis of immune cells in orthotopically implanted WT and Egfr-KO 6419c5 and 
6694c2 tumors (n=5-18/group, 2 knockout clones from each parental tumor cell clone). (H) 
Leading-edge plots from the GSEA analysis highlighting the enrichment of EGFR gene signature 
based on RNA-seq analysis of Kdm3a-KO, Klf5-KO, and Smad4-KO tumor cells (gene signatures 
were generated based on p.adj-value < 0.01 and fold change > 2). (I) Graph showing top 
enriched functional pathways from GSEA using Hallmark genesets. In (F-G), statistical 














Figure 6: Ablation of tumor cell intrinsic KLF5, SMAD4 and EGFR increases the sensitivity 
of PDA tumors to a combination immunotherapy. (A) Growth curves, waterfall plots, and overall 
survival curves of WT, Klf5-KO, Smad3-KO, Smad4-KO, Egfr-KO tumors with or without GAFCP 
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treatment. Tumor cells were subcutaneously implanted into C57BL/6 mice (2 knockout tumor cell 
clones were pooled together for this experiment, n=5/group). (B) Flow cytometric analysis of 
immune cells in subcutaneously implanted 6694c2 tumors treated with either vehicle or erlotinib 
(n=5/group). (C) Flow cytometric analysis of immune cells in orthotopically implanted 6694c2 
tumors treated with either vehicle or erlotinib (n=5/group). For subcutaneous tumors, treatment 
started on day 10 post-implantation, and tumors were collected for flow analysis 10 days later. For 
orthotopic tumors, treatment started on day 7 post-implantation and tumors were harvested for flow 
analysis 10 days later. In (A), statistical differences were calculated using two-way ANOVA with 
multiple analysis (tumor growth curves) and Log-rank (Mantel-Cox) test (survival curves). In (B), 
statistical differences were calculated using one-way ANOVA with multiple comparisons. In (C), 


















Graphical Summary: The KDM3A-KLF5-SMAD4 transcriptional axis converges on EGFR to drive 
an immunosuppressive microenvironment. Loss of KDM3A ultimately leads to downregulation of 








Supplementary Figure S1: Epigenetic profiling of PDA tumors and experimental setup.        
(A) Diagram showing the strategy for epigenetic profiling of T cell low and T cell high tumor cells 
using ATAC-seq. (B) Graph illustrating the top enriched functional pathways associated with 
differentially accessible genomic regions in T cell low (blue) and T cell high (red) tumor cells sorted 
from subcutaneously implanted PDA tumors. (C) Growth curves and waterfall plots for tumors 
treated with vehicle (n=10) or GAFCP (n=25). (D) Diagram showing the strategy for transcriptional 
profiling of sorted tumor cells derived from the 6419c5 T cell low tumor cell clone, with or without 
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GAFCP therapy. (E) Principal component analysis of RNA-seq data generated from (D) using the 
top 2000 most variable genes. (F) Leading-edge plots from the GSEA analysis highlighting the 
enrichment of the T cell low gene signature generated in our recent study (p-value < 0.05) based 






Supplementary Figure S2: DNMT1 is a tumor cell intrinsic epigenetic factor suppressing T 
cell mediated anti-tumor immunity. (A-B) Dot plots showing top genes whose sgRNAs were 
enriched in Pre-injection group in relative to Ctrl group (A) or GAFCP group (B). (C) Quantitative 
PCR analysis of Dnmt1 for validating CRISPR knockout in 6419c5 and 6694c2 tumor cells (2 
knockout clones were studied for each parental tumor cell clone). (D) Quantification of percentage 
of mice bearing tumors 3 weeks following subcutaneous injection with WT or Dnmt1-KO 6419c5 
(n=4-8/group) and 6694c2 (n=5-10/group) tumor cells (2 knockout clones were studied for each 
parental tumor cell clone). (E) Representative flow plots showing the gating strategy for 
identification of immune cells for this study. (F) Flow cytometric analysis of immune cells in 
subcutaneously implanted WT or Dnmt1-KO 6419c5 and 6694c2 tumors (n=5-6/group, 2 knockout 
clones for each parental tumor cell clone). (G) Representative flow plots showing the efficient 
depletion of CD4 and CD8 T cells. Plots are shown as a percentage of total CD3+ T cells. (H) 
Quantification of percentage of mice bearing tumors 3 weeks following subcutaneous injection of 
Dnmt1-KO 6419c5 tumor cells with or without T cell depletion (n=10/group, 2 knockout clones were 
used with 5 mice/group for each clone). In (C), statistical differences were calculated using one-







Supplementary Figure S3: Genetic ablation of tumor cell intrinsic KDM3A promotes a T-cell-
inflamed TME. (A) Dot plot showing top genes whose sgRNAs were enriched in the Ctrl group 
compared to the GAFCP group. Each dot represents a gene whose sgRNAs were enriched in Ctrl 
(blue) group, with p-value < 0.025 and good.sgRNAs > 3. Several top candidate epigenetic 
regulators are highlighted. (B) and (D) Quantitative PCR analysis of indicated genes for validating 
CRISPR efficiency in 6419c5 and 6694c2 tumor cells (2 knockout clones for every parental PDA 
tumor cell clone). (C) Flow cytometric analysis of immune cells in subcutaneously implanted 6419c5 
tumors with knockout of indicated genes (Data for WT and Kdm3a-KO are the same as Data for 
these samples in Fig. 1d) (n=5-13/group). (E) Flow cytometric analysis of immune cells in 
subcutaneously implanted 6694c2 tumors with knockout of indicated genes (Data for WT and 
Kdm3a-KO are the same as Data for these samples in Fig. 1d) (n=9-13/group). (F) Immunoblot test 
for KDM3A loss in 6419c5 and 6694c2 Kdm3a-KO tumor cell clones. (G-H) Survival curves of 
human PDA patients with top and bottom 25% expression of indicated genes, using OncoLnc tool. 
(I) Flow cytometric analysis of immune cells in implanted subcutaneously Kdm3a-WT and Kdm3a-
KO 6419c5 and 6694c2 tumors (n=9-13/group). (J) Flow cytometric analysis of immune cells in 
implanted orthotopically Kdm3a-WT and Kdm3a-KO 6419c5 and 6694c2 tumors (n=5-10/group). 
In (B-E), statistical differences were calculated using one-way ANOVA with multiple comparisons. 






Supplementary Figure S4: Transcriptional and epigenetic profiling identifies KLF5 and 
SMAD4 as potential transcriptional regulators downstream of KDM3A. (A) Diagram showing 
the strategy for transcriptional profiling of Kdm3a-WT and Kdm3a-KO tumor cells using RNA-seq. 
(B-C) Graph showing top enriched functional pathways from GSEA using Hallmark genesets. (D) 
Volcano plot displaying differentially expressed genes between sorted YFP+ tumor cells from 
Kdm3a-WT or Kdm3a-KO tumors. Each dot represents a gene (Kdm3a-WT (blue) or Kdm3a-KO 
(red), with p.adj-value < 0.05). Several antigen presentation relevant genes are highlighted. (E) 
Flow analysis of MHCI expression on tumor cells in vivo (n=9-11/group). (F) Flow analysis of MHCI 
and PD-L1 expression on tumor cells in vitro (n=3/group). (G) Heatmap showing the results from 
mass-spectrometry analysis of histones extracted from Kdm3a-WT or Kdm3a-KO 6419c5 and 
6694c2 tumor cells. (H) Genomic distribution of ChIP-seq signals, showing differential genomic 
regions of K9ac and K9me2 enriched in WT tumor cells (enrich_in_WT) or Kdm3a-KO tumor cells 
(enrich_in_KO), as well as genomic regions of KDM3A in WT tumor cells (enrich_in_WT). (I) 
Volcano plot displaying differentially expressed genes between sorted YFP+ tumor cells from 
Kdm3a-WT or Kdm3a-KO tumors (same as in d), now with transcriptional factors enriched in WT 
tumor cells highlighted. Each dot represents a gene (Kdm3a-WT (blue) or Kdm3a-KO (red), with 
p.adj-value < 0.05). Top differentially expressed transcriptional factors enriched in WT tumor cells 
are highlighted. (J) Survival curves of human PDA patients with top and bottom 25% expression of 
indicated genes, using OncoLnc tool. (K) Graph showing top predicted transcriptional regulators 
based on the RNA-seq using EnrichR analysis. Differentially expressed genes (p-adj value < 0.05) 




























Supplementary Figure S5: Genetic ablation of tumor cell intrinsic KLF5 or SMAD proteins 
promotes a T-cell-inflamed TME. (A) Quantitative PCR analysis validating CRISPR knockout of 
the indicated genes in 6694c2 tumor cells (2 knockout clones/gene). (B) Flow cytometric analysis 
of immune cells in subcutaneously implanted WT, Klf5-KO, and Smad4-KO 6694c2 tumors 
(n=10/group, two knockout clones/gene). (C) Flow cytometric analysis of immune cells in 
subcutaneously implanted 6694c2 tumors with knockout of indicated genes (Data for WT, Klf5-KO 
and Smad4-KO tumors are the same as shown in Fig. 4a) (n=1-12/group). (D) Flow cytometric 
analysis of immune cells in orthotopically implanted WT and Klf5-KO 6694c2 tumors (n=5-10/group, 
two knockout clones/gene). (E) Flow cytometric analysis of immune cells in subcutaneously 
implanted WT and Klf5-KO 6419c5 tumors (n=4-6/group, two clones/gene). (F) Quantitative PCR 
analysis validating CRISPR knockout of Klf5 in 6419c5 tumor cells (2 knockout clones/gene). (G) 
Diagram showing the strategy for transcriptional profiling of WT, Klf5-KO and Smad4-KO tumor 
cells using RNA-seq. In (A-C) and (F), statistical differences were calculated using one-way 
ANOVA with multiple comparisons. In (D) and (E), statistical differences were calculated using 












Supplementary Figure S6: Molecular profiling identifies EGFR as a tumor cell intrinsic factor 
regulating the immune TME and sensitivity to a combination immunotherapy.        (A) 
Transcript per million (TPM) of Egfr based on RNA-seq quantification. (B) TPM of Egfr based on 
RNA-seq quantification of TGFβ treated tumor cells. (C) Survival curves of human PDA patients 
with top and bottom 25% expression of indicated genes, using OncoLnc tool. (D) Quantitative PCR 
analysis of indicated genes for validating CRISPR efficiency in 6419c5 and 6694c2 tumor cells (2 
knockout clones/gene). (E) Flow cytometric analysis of immune cells in subcutaneously implanted 
WT or Egfr-KO 6419c5 and 6694c2 tumors (n=7-16/group, two knockout tumor cell clones from 
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each parental tumor cell clone). (F) Flow cytometric analysis of immune cells in orthotopically 
implanted WT or Egfr-KO 6419c5 and 6694c2 tumors (n=5-18/group, two knockout tumor cell 
clones from each parental PDA tumor cell clone). (G) Top: Venn diagram showing the overlap 
among RNA-seq analysis for WT, Klf5-KO, Smad4-KO, and Egfr-KO tumors. Bottom: Heatmap 
showing expression of the 70 overlapping genes in the Egfr-KO tumors. In (D) statistical differences 
were calculated using one-way ANOVA with multiple comparisons. In (E-F) statistical differences 




















Supplementary Figure S7: Erlotinib treatment increases intratumoral T cell infiltration.    (A) 
Flow analysis of immune cells in subcutaneously implanted 6694c2 tumors with or without erlotinib 
(n=5/group). (B) Flow analysis of immune cells in orthotopically implanted 6694c2 tumors with or 
without erlotinib (n=5/group). (C) Flow analysis of immune cells in subcutaneously implanted 
6419c5 tumors treated with either vehicle or erlotinib (n=5/group). (D) Flow analysis of immune 
cells in orthotopically implanted 6419c5 tumors with or without treatment of erlotinib (n=5/group). 
In (A) and (C), statistical differences were calculated using one-way ANOVA with multiple 
comparisons. In (B) and (D), unpaired Student’s t-test was used.  
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CHAPTER 4: Discussion and Future Directions 
 
 
Regulation of H3K36me2 in epithelial plasticity: implications beyond cancer  
While EMT has been widely studied in cancer, it was originally identified in embryonic 
studies. During embryogenesis, EMT and MET are required for several processes, including 
gastrulation, neural crest migration and differentiation, and organogenesis. Perturbations in any of 
the pathways involved in EMT/MET result in developmental disorders of varying severity. For 
example, Wolf-Hirschhorn Syndrome (WHS) is a rare congenital disorder characterized by a 
constellation of phenotypes suggestive of neural crest impairments, including craniofacial, cardiac, 
neurodevelopmental, and skeletal defects. WHS is molecularly defined by the partial deletion of 
the short arm of chromosome 4 (4p), a region that includes our own candidate of interest, NSD2 
(also known as Wolf Hirschhorn Candidate 1, WHSC1) (116). Though several other genes are also 
found in this deleted region, NSD2 has emerged as the likely pathogenic candidate for WHS, as 
genetic deletion of Nsd2 in a mouse model closely mimicked the human syndrome (115). Still, 
decades later, how exactly NSD2 lends itself to WHS’s clinical presentation remains largely 
unknown. Given these observations and our reported findings on NSD2 and its role in regulating 
epithelial plasticity in cancer, we hypothesize that NSD2, and more broadly global H3K36me2 
levels, affects EMT/MET during normal embryonic development, particularly neural crest migration 
and/or differentiation.  
Our approach will include the use of histone point mutants, which have emerged as new 
tools to study the effects of specific histone modifications in different contexts. By inducing the 
expression of the mutant H3.3K36M in certain tissue types in a transgenic mouse model, two 
studies reported defects in the differentiation of adipocytes, myocytes, and lymphocytes (97,114). 
While these findings suggest that global loss of H3K36me2/3 have severe consequences for 
tissues of mesenchymal origin, they do not take into account the earlier stages of development in 
which EMT/MET are involved, such as gastrulation or neural crest migration/differentiation. To 
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address these stages we plan on inducing the K36M mutant, first in the entire developing blastocyst 
via a Sox2-Cre, and then in a neural crest population-specific manner via a Wnt1-Cre. Future work 
will also include rigorous embryonic staging and phenotyping, as well as molecular characterization 
of different cell populations. These studies seek to extend the implications of our studies beyond 
tumor biology to form a more generalizable application of our proposed model. 
An interesting observation that emerged from this study was that though >10,000 
H3K36me2 loci were lost with Nsd2 ablation, <200 enhancers/genes were regulated. This touches 
on a major question in the field of chromatin biology, which is how and even to what extent do 
epigenetic alterations lead to very specific changes in gene expression. For a histone mark as 
widely found as H3K36me2, this is particularly challenging to answer. There are three possible 
explanations for this: 1) many of these mostly intergenic loci redundantly regulate the same set of 
genes, 2) the majority of these loci are not actually involved in gene regulation, and 3) chromatin 
readers, whose expression and/or activity are context-dependent and tightly regulated, are 
responsible for the specificity of transcriptional output. Future work will seek to address each of 
these points and identify a more concrete molecular mechanism underlying our model. These 
studies will also contribute to our basic understanding of the epigenetic basis of gene regulation.      
 
Integrating epithelial plasticity with microenvironmental plasticity 
While the TME secretes various signaling molecules known to induce EMT, a growing body 
of literature suggests that the cancer cell secretome following EMT is also associated with 
significant changes in the immune TME. Specifically, poorly-differentiated carcinomas whose 
cancer cells have a predominantly mesenchymal histology tend to be associated with increased 
vascularity and a pro-inflammatory/immunosuppressive immune infiltrate  (222,223). This in turn 
may enable tumor cells to evade immune attack, rendering them resistant to the effects of 
immunotherapy. Since we had found that loss of NSD2 (or any mechanism that would globally 
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decrease H3K36me2 levels) induces the epithelial state, it would be interesting to see whether this 
also leads to an influx of T cells into the tumor. If so, we would further determine the mechanism 
by which the mesenchymal state drives immunosuppression. This can be investigated in several 
directions, including neoantigen number and diversity, regulation of the antigen-
recognition/presentation apparatus (i.e. MHC), secretion of immunosuppressive cytokines and 
chemokines (i.e. CSF2 and PTGS2), and interferon (IFN) activity. To further characterize EMT-
induced changes to the microenvironment, we will also profile other stromal elements, including 
vasculature and different fibroblast populations, and determine whether and how they contribute to 
the immune TME. Ultimately, we would like to see whether inhibiting EMT is sufficient to sensitize 
PDA tumors to combination immunotherapy. This could represent a powerful new treatment 
paradigm that would address the top causes of cancer-related mortality, including metastasis and 
therapeutic resistance.  
 
Epigenetic priming: a new treatment paradigm? 
Maintenance of a particular cellular state relies on precise and accurate regulation of the 
chromatin landscape across space and time. Dysregulation of epigenetic processes disrupts 
normal transcriptomic programs, resulting in aberrant gene activation and silencing. The 
consequences of these changes depend on the genomic location and tissue-specific contexts in 
which they occur, and can lead to a multitude of new cellular states. In many cancers, this 
epigenetic plasticity can drive both malignant transformation and tumor progression. The studies 
presented in this thesis demonstrate two such examples in which tumor cell-intrinsic epigenetic 
perturbations lead to cellular plasticity in both a cell autonomous and non-cell autonomous manner. 
These results also have important therapeutic implications, and suggest the potential for designing 
synthetically lethal drug combinations. Synthetic lethality is defined as the interaction between two 
co-essential genes such that inhibiting the function of either gene separately results in cell survival, 
but inhibiting the function of both genes results in cell death. This two-hit approach seeks to both 
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engineer and exploit specific vulnerabilities in a tumor, and inhibitors of epigenetic processes may 
be particularly useful in this manner. 
While inhibitors against epigenetic modifiers have gained traction in clinical trials and have 
been shown to be effective in specific tumor types, targeting epigenetic processes alone may not 
be sufficient in most cancers. However, these inhibitors can still play a role by “epigenetically 
priming” the tumor in the following ways: 1) the widescale changes in chromatin landscape and 
subsequent transcriptomic rewiring are likely to unearth secondary novel therapeutic vulnerabilities 
that previously did not exist, and 2) by forcing tumor cells to adopt a specific, uniform cellular 
state/differentiation program, epigenetic priming may serve to “normalize” tumor heterogeneity, 
leading to a more molecularly consistent disease state. Two recent studies in PDA demonstrate 
this principle (51,52). Genovese et al. found that loss of the SWI/SNF subunit SMARCB1 leads to 
the formation of poorly differentiated tumors that have activated endoplasmic-reticulum (ER) stress-
induced survival pathways. These molecular changes rendered SMARCB1 KO tumors particularly 
susceptible to pharmacological inhibition of the cellular proteostatic machinery and the ER-stress 
pathway. In another study, Andricovich et al. found that loss of the histone demethylase KDM6A 
also increases the incidence of poorly differentiated tumors. A small molecule screen identified 
bromodomain inhibitors such as JQ1 and iBET as being synthetically lethal with loss of KDM6A. In 
both cases, the first epigenetic hit induced a switch in cellular state that rendered the tumor 
exquisitely sensitive to another therapeutic intervention. We can explore similar possibilities in the 
two contexts presented in this thesis and investigate how epigenetic manipulation of cellular and 
microenvironmental plasticity can be therapeutically leveraged. 
Given its roles in metastasis and drug resistance, EMT has long been considered a 
mechanism worth targeting. Indeed, small molecule inhibitors and neutralizing antibodies directed 
against various signaling pathways have been tested in both preclinical and clinical trials to minimal 
success. In particular, the diverse and context-specific mechanisms underlying EMT have 
complicated these efforts. EMT is associated with the activity of various signaling pathways that 
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converge on a core group of EMT-TFs, whose expression levels and functions vary across different 
developmental, homeostatic, and malignant settings. Our finding that H3K36me2 regulation is a 
conserved and required feature of carcinoma-associated epithelial plasticity that lies upstream of 
these various pathways may represent a new therapeutic target that overcomes the molecular 
heterogeneity associated with EMT. However, though reversing EMT would help to mitigate therapy 
resistance and decrease the number of disseminated tumor cells, its reverse process, MET, has 
also been found to promote proliferation and colonization at distal sites (3,4,224). Such secondary 
consequences would counteract the intended benefits of inhibiting EMT. Furthermore, inhibiting 
EMT would likely have minimal impact on baseline disease burden, leaving the already existing 
tumor foci relatively unchecked as they continue to proliferate. A potential solution to these 
concerns is to consider adjuvant therapies that would be synthetically lethal with EMT-inhibiting 
agents. To this end, we propose high throughput pharmacologic and genetic screens to extend our 
own findings and determine those compounds or gene candidates that are synthetically lethal with 
the loss of Nsd2/global H3K36me2. Through these studies we aim to find and design treatment 
combinations that would not only inhibit epithelial plasticity and subsequent metastatic events, but 
also more effectively eradicate the remaining tumor burden.  
In the second study of this thesis, we demonstrate that epigenetic reprogramming of tumor 
cells can also lead to dramatic alterations to the surrounding microenvironment. Here we identified 
the histone demethylase KDM3A as a tumor cell-intrinsic epigenetic driver of the T cell-low 
environment in PDA. Loss of KDM3A not only facilitates intratumoral T cell infiltration, but also 
sensitizes the tumor to combination immunotherapy. Mechanistically, we found that KDM3A 
regulates the expression of EGFR, and provide evidence suggesting that the established EGFR 
small molecule inhibitor erlotinib may similarly enhance the efficacy of our immunotherapy regimen. 
This has profound implications for the treatment of PDA, which responds poorly to most therapies. 
Previous clinical trials using erlotinib and newer generations of EGFR inhibitors yielded 
disappointing results on survivorship, thus dismissing them as a first line therapeutic option. 
Similarly, immune checkpoint blockade, either alone or in combination with chemotherapy, remains 
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mostly ineffective in PDA. Our findings indicate that the use of an EGFR inhibitor as a neoadjuvant 
to immunotherapy may be the key to unlocking their respective efficacies, and such a regimen will 
be thoroughly explored in future preclinical studies. Still, we also report that different tumors varied 
in their response to erlotinib treatment, and that the levels of T cell infiltration were not as 
consistently upregulated as seen with genetic loss of KDM3A. Though a potent KDM3A-specific 
inhibitor has yet to be synthesized, we hypothesize that such a drug may be a more robust 
alternative to erlotinib as an adjuvant to immunotherapy. In this case, epigenetic reprogramming 
mediated by KDM3A inhibition would be the important first hit to prime the tumor for subsequent 
immunotherapy. 
Monotherapy is rarely successful in treating cancer. Often it takes different classes of drugs 
in combination with different treatment modalities to induce regression or remission. Synthetic lethal 
drug combinations represent a more targeted approach that both engineers and exploits specific 
changes within the cancer. With their ability to target both cellular and microenvironmental changes, 
epigenetic inhibitors may be particularly effective as the first hit in this two-hit approach. Further 
work is necessary to better understand the roles epigenetic dysregulation plays in cancer plasticity 
and to identify new therapeutically tractable options that these studies may reveal. 
 
Concluding remarks  
My thesis work sought to investigate the epigenetic basis of tumor plasticity, a phenomenon 
frequently associated with some of the most lethal aspects of cancer, including metastasis and 
therapy resistance. We chose to focus our studies on epigenetic mechanisms from the very 
beginning, hypothesizing that the changes in chromatin observed in developmental and 
homeostatic examples of cellular plasticity are likely recapitulated and/or hijacked during tumor 
progression. Broadly speaking, loss of normal identity is one of the most fundamental definitions of 
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cancer. It is thus intuitive to assume that epigenetic reprogramming features strongly in malignant 
cell fate changes.  
The studies discussed represent two of many examples by which tumor cells are able to 
adopt different states along a phenotypic spectrum. On one hand, EMT is one of the most widely 
studied examples of cellular plasticity in cancer. Unfortunately, just as there are hundreds of such 
studies, so too are there multiple mechanisms that seem to drive EMT, which depend on the cell 
types, inducing agents, and experimental settings employed. Here, we identified a more unifying 
mechanism that can underlie EMT across multiple contexts. Though multiple signaling pathways 
and transcription factors can contribute to EMT, we argue that most paths stem from the global 
regulation of the histone mark H3K36me2. Thus, our model may serve to reconcile and clarify these 
diverse, context-dependent mechanisms. In our second study, we identified an epigenetic-
transcriptional axis that drives the T cell high and low states. In doing so, our data also suggests 
that these two states do indeed represent stable cellular identities, a paradigm that can change the 
way we think about tumor cells and their relationship with their surrounding microenvironment. We 
further explored the therapeutic implications of epigenetic reprogramming and have found a way to 
potentially repurpose two forms of therapy that previously yielded disappointing results in clinical 
trials. Collectively, the work presented demonstrates the importance of understanding the ways by 
which epigenetic programs drive various cancer phenotypes.  
Finally, both of the studies presented in this thesis were initiated from CRISPR screens, 
highlighting the long-lasting power of genetic screening. Though the screening modality continues 
to change over time, the concept of using high throughput genetic perturbations to generate tens 
and hundreds of hypotheses remains a central component of basic investigative biology. So long 
as the experimental system is tractable, implementing a genetic screen can yield a wealth of new 
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